RespireRx Pharmaceuticals (RSPI) 10-Q 15 Oct 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Oct. 14, 2018
Document And Entity Information
Entity Registrant Name	RespireRx Pharmaceuticals Inc.
Entity Central Index Key	849,636
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		3,588,434
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,018

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 874	$ 84,902
Advance payment on research contract	48,912	48,912
Prepaid expenses, including current portion of long-term prepaid insurance of $14,945 at June 30, 2018 and December 31, 2017	82,598	42,897
Total current assets	132,384	176,711
Long-term prepaid insurance, net of current portion of $14,945 at June 30, 2018 and December 31, 2017	10,586	18,059
Total assets	142,970	194,770
Current liabilities:
Accounts payable and accrued expenses, including $305,031 and $228,939 payable to related parties at June 30, 2018 and December 31, 2017, respectively	3,134,464	2,922,013
Accrued compensation and related expenses	836,850	479,300
Convertible notes payable, currently due and payable on demand, including accrued interest of $53,205 and $98,646 at June 30, 2018 and December 31, 2017, respectively (Note 4)	178,205	374,646
Note payable to SY Corporation, including accrued interest of $291,124 and $267,335 at June 30, 2018 and December 31, 2017, respectively (payment obligation currently in default – Note 4)	719,181	583,827
Notes payable to officers, including accrued interest of $38,926 and $26,538 as of June 30, 2018 and December 31, 2017, respectively (Note 4)	294,126	181,738
Other short-term notes payable	49,272	8,630
Total current liabilities	5,212,098	4,550,154
Commitments and contingencies (Note 8)
Stockholders’ deficiency: (Note 6)
Series B convertible preferred stock, $0.001 par value; $0.6667 per share liquidation preference; aggregate liquidation preference $25,001; shares authorized: 37,500; shares issued and outstanding: 11 common shares issuable upon conversion at 0.00030 common shares per Series B share	21,703	21,703
Common stock, $0.001 par value; shares authorized: 65,000,000; shares issued and outstanding: 3,349,619 and 3,065,261 at June 30, 2018 and December 31, 2017, respectively (Note 2)	3,350	3,065
Additional paid-in capital	158,090,123	157,422,110
Accumulated deficit	(163,184,304)	(161,802,262)
Total stockholders' deficiency	(5,069,128)	(4,355,384)
Total liabilities and stockholders’ deficiency	$ 142,970	$ 194,770

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Long term prepaid insurance current portion	$ 14,945	$ 14,945
Long-term prepaid insurance net of current portion	14,945	14,945
Accounts payable and accrued expenses to related party	$ 305,031	$ 228,939
Preferred stock, par value	$ 0.001
Preferred stock, shares authorized	5,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	65,000,000	65,000,000
Common stock, shares issued	3,349,619	3,065,261
Common stock, shares outstanding	3,349,619	3,065,261
Officers [Member]
Accrued interest	$ 38,926	$ 26,538
SY Corporation [Member]
Accrued interest	291,124	267,335
Convertible Notes Payable [Member]
Accrued interest	$ 53,205	$ 98,646
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation preference, per share	$ 0.6667	$ 0.6667
Preferred stock, liquidation preference value	$ 25,001	$ 25,001
Preferred stock, shares authorized	37,500	37,500
Preferred stock, shares issued	11	11
Preferred stock, shares outstanding	11	11
Preferred stock shares issuable upon conversion, per share	$ 0.00030	$ 0.00030

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Operating expenses:
General and administrative, including $202,370 and $688,388 to related parties for the three months ended June 30, 2018 and 2017, respectively, and $409,964 and $1,060,037 to related parties for the six months ended June 30, 2018 and 2017, respectively	$ 432,932	$ 974,774	$ 787,775	$ 2,011,076
Research and development, including $122,704 and $365,743 to related parties for the three months ended June 30, 2018 and 2017, respectively, and $245,213 and $570,073 to related parties for the six months ended June 30, 2018 and 2017, respectively	153,892	574,743	305,227	959,127
Total operating expenses	586,824	1,549,517	1,093,002	2,970,203
Loss from operations	(586,824)	(1,549,517)	(1,093,002)	(2,970,203)
Loss on extinguishment of debt and other liabilities in exchange for equity	(49,625)		(105,253)
Interest expense, including $10,615 and $3,869 to related parties for the three months ended June 30, 2018 and 2017, respectively, and $19,225 and $7,696 to related parties for the six months ended June 30, 2018 and 2017, respectively	(33,795)	(26,283)	(61,068)	(51,321)
Foreign currency transaction gain (loss)	34,881	(8,266)	(111,565)	(31,688)
Net loss	(635,363)	(1,584,066)	(1,382,042)	(3,053,212)
Net loss attributable to common stockholders	$ (635,363)	$ (1,584,066)	$ (1,382,042)	$ (3,053,212)
Net loss per common share - basic and diluted	$ (0.20)	$ (0.69)	$ (0.44)	$ (1.37)
Weighted average common shares outstanding - basic and diluted	3,197,932	2,289,045	3,141,909	2,224,515

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
General and administrative expense to related parties	$ 202,370	$ 688,388	$ 409,964	$ 1,060,037
Research and development expenses to related parties	122,704	365,743	245,213	570,073
Interest expense to related parties	$ 10,615	$ 3,869	$ 19,225	$ 7,696

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2017
Series B Convertible Preferred Stock [Member]
Balance beginning		$ 21,703
Balance beginning, shares		37,500
Fair value of common stock options issued to consultants
Fair value of common stock options issued to consultants, shares
Common stock issued related to extinguishment of convertible notes
Common stock issued related to extinguishment of convertible notes, shares
Net loss
Balance ending	$ 21,703	$ 21,703	$ 21,703
Balance ending, shares	37,500	37,500	37,500
Common Stock [Member]
Balance beginning		$ 3,065
Balance beginning, shares		3,065,261
Fair value of common stock options issued to consultants
Fair value of common stock options issued to consultants, shares
Common stock issued related to extinguishment of convertible notes		$ 285
Common stock issued related to extinguishment of convertible notes, shares		284,358
Net loss
Balance ending	$ 3,350	$ 3,350	$ 3,065
Balance ending, shares	3,349,619	3,349,619	3,065,261
Additional Paid-in Capital [Member]
Balance beginning		$ 157,422,110
Fair value of common stock options issued to consultants		349,777
Common stock issued related to extinguishment of convertible notes		318,236
Net loss
Balance ending	$ 158,090,123	158,090,123	$ 157,422,110
Accumulated Deficit [Member]
Balance beginning		(161,802,262)
Fair value of common stock options issued to consultants
Common stock issued related to extinguishment of convertible notes
Net loss		(1,382,042)
Balance ending	(163,184,304)	(163,184,304)	(161,802,262)
Balance beginning		(4,355,384)
Fair value of common stock options issued to consultants		349,777
Common stock issued related to extinguishment of convertible notes		318,521
Net loss	(635,363)	(1,382,042)	(4,291,483)
Balance ending	$ (5,069,128)	$ (5,069,128)	$ (4,355,384)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net loss	$ (1,382,042)	$ (3,053,212)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		3,283
Stock-based compensation expense included in - General and administrative expenses	14,248	1,127,052
Stock-based compensation expense included in - Research and development expenses		595,201
Foreign currency transaction loss	111,565	31,688
Loss on extinguishment of debt	105,253
Loss on extinguishment of other liabilities	11,154
(Increase) decrease in -
Prepaid expenses	(32,228)	(21,319)
Increase (decrease) in -
Accounts payable and accrued expenses	336,479	276,969
Accrued compensation and related expenses	557,900	533,924
Accrued interest payable	93,643	50,021
Net cash used in operating activities	(184,028)	(456,393)
Cash flows from financing activities:
Proceeds from sale of common stock units		350,000
Proceeds from issuance of notes payable to officers	100,000
Other short-term notes payable		45,201
Net cash provided by financing activities	100,000	395,201
Cash and cash equivalents:
Net (decrease) increase	(84,028)	(61,192)
Balance at beginning of period	84,902	92,040
Balance at end of period	874	30,848
Supplemental disclosures of cash flow information:
Interest	682	1,274
Non-cash financing activities:
10% convertible notes payable, including accrued interest of $62,267, exchanged for common stock	213,266
Accrual of fees payable to placement agent in connection with the sale of common stock units		20,000
Fair value of common stock warrants issued to placement agent in connection with the sale of common stock units		27,648
Reclassification of non-permanent equity		$ 185,000

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)	Jun. 30, 2018USD ($)
Percentage of convertible debt	8.93%
Convertible Notes Payable [Member]
Percentage of convertible debt	10.00%
Accrued interest payable	$ 62,267

Organization and Basis of Prese

Organization and Basis of Presentation	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	1. Organization and Basis of Presentation Organization RespireRx Pharmaceuticals Inc. (“RespireRx”) was formed in 1987 under the name Cortex Pharmaceuticals, Inc. to engage in the discovery, development and commercialization of innovative pharmaceuticals for the treatment of neurological and psychiatric disorders. On December 16, 2015, RespireRx filed a Certificate of Amendment to its Second Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to amend its Second Restated Certificate of Incorporation to change its name from Cortex Pharmaceuticals, Inc. to RespireRx Pharmaceuticals Inc. While developing potential applications for respiratory disorders, RespireRx has retained and expanded its ampakine intellectual property and data with respect to neurological and psychiatric disorders and is considering developing certain potential products in this platform, pending additional financing and/or strategic relationships. In August 2012, RespireRx acquired Pier Pharmaceuticals, Inc. (“Pier”), which is now its wholly-owned subsidiary. Basis of Presentation The condensed consolidated financial statements are of RespireRx and its wholly-owned subsidiary, Pier (collectively referred to herein as the “Company” or “we” or “our” unless the context indicates otherwise). The condensed consolidated financial statements of the Company at June 30, 2018 and for the three and six month periods ended June 30, 2018 and 2017, are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) have been made that are necessary to present fairly the condensed consolidated financial position of the Company as of June 30, 2018, the results of its condensed consolidated operations for the three and six month periods ended June 30, 2018 and 2017, and its condensed consolidated cash flows for the six months ended June 30, 2018 and 2017. Condensed consolidated operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The consolidated balance sheet at December 31, 2017 has been derived from the Company’s audited consolidated financial statements at such date. The condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and other information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, as filed with the SEC.

Business

Business	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	2. Business The mission of the Company is to develop innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling. We are developing treatment options that address conditions that affect millions of people, but for which there are few or poor treatment options, including obstructive sleep apnea (“OSA”), attention deficit hyperactivity disorder (“ADHD”) and recovery from spinal cord injury (“SCI”), as well as certain neurological orphan diseases such as Fragile X Syndrome. RespireRx is developing a pipeline of new drug products based on our broad patent portfolios for two drug platforms: cannabinoids, including dronabinol (“∆9-THC”), and the ampakines, proprietary compounds that positively modulate AMPA-type glutamate receptors to promote neuronal function. RespireRx is developing a number of potential products. From the cannabinoid platform, two Phase 2 clinical trials have been completed demonstrating the ability of dronabinol to significantly reduce the symptoms of OSA, which management believes is potentially a multi-billion dollar market. Subject to raising sufficient financing, we believe that we have put most of the necessary pieces into place to rapidly initiate a Phase 3 clinical trial program. By way of definition, when a new drug is allowed by the United States Food and Drug Administration (“FDA”) to be tested in humans, Phase 1 clinical trials are conducted in healthy people to determine safety and pharmacokinetics. If successful, Phase 2 clinical trials are conducted in patients to determine safety and preliminary efficacy. Phase 3 trials, large scale studies to determine efficacy and safety, are the final step prior to seeking FDA approval to market a drug. From our ampakine platform, our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 efficacy trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression. CX717 has completed a Phase 2 trial demonstrating the ability to significantly reduce the symptoms of ADHD. In an early Phase 2 study, CX1739 improved breathing in patients with central sleep apnea. Preclinical studies have highlighted the potential ability of these ampakines to improve motor function in animals with spinal injury. Subject to raising sufficient financing (of which no assurance can be provided), we believe that we will be able to rapidly initiate a human Phase 2 study with CX1739 in patients with spinal cord injury and a human Phase 2B study in patients with ADHD with either CX717 or CX1739. RespireRx is considering an internal restructuring plan that contemplates spinning out the cannabinoid platform into what would initially be a wholly-owned subsidiary that the Company currently intends would ultimately have its own management team and board of directors. This spin-out company would be tasked with raising financing in order to develop and commercialize the dronabinol platform for the treatment of OSA. Going Concern The Company’s condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred net losses of $1,382,042 for the six months ended June 30, 2018 and $4,291,483 for the fiscal year ended December 31, 2017, and negative operating cash flows of $184,028 for the six months ended June 30, 2018 and $697,009 for the fiscal year ended December 31, 2017. The Company also had a stockholders’ deficiency of $5,069,128 at June 30, 2018 and expects to continue to incur net losses and negative operating cash flows for at least the next few years. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern, and the Company’s independent registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended December 31, 2017, expressed substantial doubt about the Company’s ability to continue as a going concern. The Company is currently, and has for some time, been in significant financial distress. It has extremely limited cash resources and current assets and has no ongoing source of sustainable revenue. Management is continuing to address various aspects of the Company’s operations and obligations, including, without limitation, debt obligations, financing requirements, intellectual property, licensing agreements, legal and patent matters and regulatory compliance, and has taken steps to continue to raise new debt and equity capital to fund the Company’s business activities from both related and unrelated parties. The Company is continuing its efforts to raise additional capital in order to be able to pay its liabilities and fund its business activities on a going forward basis, including the pursuit of the Company’s planned research and development activities. The Company regularly evaluates various measures to satisfy the Company’s liquidity needs, including development and other agreements with collaborative partners and, when necessary, seeking to exchange or restructure the Company’s outstanding securities. The Company is evaluating certain changes to its operations and structure to facilitate raising capital from sources that may be interested in financing only discrete aspects of the Company’s development programs. Such changes could include a significant reorganization, which may include the formation of one or more subsidiaries into which one or more programs may be contributed. As a result of the Company’s current financial situation, the Company has limited access to external sources of debt and equity financing. Accordingly, there can be no assurances that the Company will be able to secure additional financing in the amounts necessary to fully fund its operating and debt service requirements. If the Company is unable to access sufficient cash resources, the Company may be forced to discontinue its operations entirely and liquidate.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of RespireRx and its wholly-owned subsidiary, Pier. Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high quality financial institutions. The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. Cash Equivalents The Company considers all highly liquid short-term investments with maturities of less than three months when acquired to be cash equivalents. Fair Value of Financial Instruments The authoritative guidance with respect to fair value of financial instruments established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The carrying amounts of financial instruments (consisting of cash, cash equivalents, advances on research grants and accounts payable and accrued expenses) are considered by the Company to be representative of the respective fair values of these instruments due to the short-term nature of those instruments. With respect to the note payable to SY Corporation and the convertible notes payable, management does not believe that the credit markets have materially changed for these types of borrowings since the original borrowing date. The Company considers the carrying amounts of the notes payable to officers, inclusive of accrued interest, to be representative of the respective fair values of such instruments due to the short-term nature of those instruments and their terms. Deferred Financing Costs Costs incurred in connection with ongoing debt and equity financings, including legal fees, are deferred until the related financing is either completed or abandoned. Costs related to abandoned debt or equity financings are charged to operations in the period of abandonment. Costs related to completed debt financings are presented as a direct deduction from the carrying amount of the related debt liability (see “Capitalized Financing Costs” below). Costs related to completed equity financings are charged directly to additional paid-in capital. Capitalized Financing Costs The Company presents debt issuance costs related to debt liability in its condensed consolidated balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with the presentation for debt discounts. Convertible Notes Payable Original Issuance of Notes and Warrants Convertible notes are evaluated to determine if they should be recorded at amortized cost. To the extent that there are associated warrants, the convertible notes and warrants are evaluated to determine if there are embedded derivatives to be identified, bifurcated and valued at fair value in connection with and at the time of such financing. 2018 Notes Exchange In cases where debt or other liabilities are exchanged for equity, the Company compares the value of debt, inclusive of accrued interest, if applicable, being exchanged for equity to the value of the equity issued and records any loss or gain as a result of such exchange. See Note 4. Notes Payable. Extinguishment of Debt The Company accounts for the extinguishment of debt in accordance with GAAP by comparing the carrying value of the debt to the fair value of consideration paid or assets given up and recognizing a loss or gain in the condensed consolidated statement of operations in the amount of the difference in the period in which such transaction occurs. Equipment Equipment is recorded at cost and depreciated on a straight-line basis over their estimated useful lives, which range from three to five years. All equipment was fully depreciated as of June 30, 2018. Long-Term Prepaid Insurance Long-term prepaid insurance represents the premium paid in March 2017 for directors’ and officers’ insurance tail coverage, which is being amortized on a straight-line basis over the policy period of six years. The amount amortizable in the ensuing twelve-month period is recorded as a current asset in the Company’s condensed consolidated balance sheet at each reporting date. Impairment of Long-Lived Assets The Company reviews its long-lived assets, including long-term prepaid insurance, for impairment whenever events or changes in circumstances indicate that the total amount of an asset may not be recoverable, but at least annually. An impairment loss is recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than the asset’s carrying amount. The Company has not deemed any long-lived assets as impaired at June 30, 2018. Stock-Based Compensation The Company periodically issues common stock and stock options to officers, directors, Scientific Advisory Board members, consultants and other vendors for services rendered. Such issuances vest and expire according to terms established at the issuance date of each grant. The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards. The Company accounts for stock-based payments to Scientific Advisory Board members, consultants and other vendors by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached, or (b) at the date at which the necessary performance to earn the equity instruments is complete. Stock grants, which are generally subject to time-based vesting, are measured at the grant date fair value and charged to operations ratably over the vesting period. Stock options granted to members of the Company’s Scientific Advisory Board, outside consultants and other vendors are revalued each reporting period until vested to determine the amount to be recorded as an expense in the respective period. As the stock options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the value on the date of vesting. The fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock. Stock options and warrants issued to non-employees as compensation for services to be provided to the Company or in settlement of debt are accounted for based upon the fair value of the services provided or the estimated fair value of the stock option or warrant, whichever can be more clearly determined. Management uses the Black-Scholes option-pricing model to determine the fair value of the stock options and warrants issued by the Company. The Company recognizes this expense over the period in which the services are provided. For stock options requiring an assessment of value during the six months ended June 30, 2018, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model using the following assumptions: Risk-free interest rate 2.64-2.68 % Expected dividend yield 0 % Expected volatility 186.00 to 190.55 % Expected life in years 4.52 to 5.00 For stock options requiring an assessment of value during the six months ended June 30, 2017, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model using the following assumptions: Risk-free interest rate 1.89 % Expected dividend yield 0 % Expected volatility 140.00 % Expected life 3.4 to 5 years The Company recognizes the fair value of stock-based compensation in general and administrative costs and in research and development costs, as appropriate, in the Company’s condensed consolidated statements of operations. The Company issues new shares of common stock to satisfy stock option and warrant exercises. There were no stock options exercised during the six months ended June 30, 2018 and 2017. There were no warrants issued in the six months ended June 30, 2018 and 2017 requiring such assessment. Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The Company may have had a change in control under these Sections. However, the Company does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss and tax credit carryforwards until the time that it anticipates it will be able to utilize these tax attributes. As of June 30, 2018, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of June 30, 2018, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense. Foreign Currency Transactions The note payable to SY Corporation, which is denominated in a foreign currency (the South Korean Won), is translated into the Company’s functional currency (the United States Dollar) at the exchange rate on the balance sheet date. The foreign currency exchange gain or loss resulting from translation is recognized in the related condensed consolidated statements of operations. Research and Development Research and development costs include compensation paid to management directing the Company’s research and development activities, and fees paid to consultants and outside service providers and organizations (including research institutes at universities), and other expenses relating to the acquisition, design, development and clinical testing of the Company’s treatments and product candidates. Research and development costs incurred by the Company under research grants are expensed as incurred over the life of the underlying contracts, unless the terms of the contract indicate that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis. On May 6, 2016, the Company made an advance payment to Duke University with respect to the Phase 2A clinical trial of CX1739. At June 30, 2018, an asset balance of $48,912 remained from the advance payment. License Agreements Obligations incurred with respect to mandatory payments provided for in license agreements are recognized ratably over the appropriate period, as specified in the underlying license agreement, and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Obligations incurred with respect to milestone payments provided for in license agreements are recognized when it is probable that such milestone will be reached and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Payments of such liabilities are made in the ordinary course of business. Patent Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred. Earnings per Share The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Net income (loss) attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed preferred stock dividends declared, amortized or accumulated. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive. At June 30, 2018 and 2017, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. June, 2018 2017 Series B convertible preferred stock 11 11 Convertible notes payable 15,669 31,398 Common stock warrants 1,464,415 688,198 Common stock options 4,323,317 1,987,749 Total 5,803,412 2,707,356 Reclassifications Certain comparative figures in 2017 have been reclassified to conform to the current quarter’s presentation. These reclassifications were immaterial, both individually and in the aggregate. Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Notes Payable	4. Notes Payable Convertible Notes Payable The convertible notes sold to investors in 2014 and 2015, which aggregated a total of $579,500, had a fixed interest rate of 10% per annum and those that remain outstanding are convertible into common stock at a fixed price of $11.3750 per share. The convertible notes have no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events. The warrants to purchase 50,945 shares of common stock issued in connection with the sale of the convertible notes were exercisable at a fixed price of $11.3750 per share, provided no right to receive a cash payment, and included no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events. All such warrants have either been exchanged as part of April and May 2016 note and warrant exchange agreements or expired on September 15, 2016. The Company determined that there were no embedded derivatives to be identified, bifurcated and valued in connection with this financing. The maturity date of the convertible notes was extended to September 15, 2016 and included the issuance of 27,936 additional warrants to purchase common stock, exercisable at $11.375 per share of common stock expiring on September 15, 2016. The convertible notes (including those for which default notices have been received) consist of the following at June 30, 2018 and December 31, 2017: June 30, 2018 December 31, 2017 Principal amount of notes payable $ 125,000 $ 276,000 Add accrued interest payable 53,205 98,646 $ 178,205 $ 374,646 Between October 3, 2016 and October 25, 2016, the Company received several notices of default from holders of convertible notes. The effect of such notices of default was to increase the annual interest rate from 10% to 12% with respect to the convertible notes to which such notices applied. On February 28, 2018, two of such convertible notes were exchanged for common stock of the Company and were extinguished. The Company measured the fair value of the shares of common stock issued to the holder in respect to the extinguishment of the two convertible notes as compared to the aggregate of principal and interest on such notes and recorded a loss of 66,782 which is the amount of the excess fair value paid as compared to the aggregate principal and interest extinguished. The total amount of principal and accrued interest that was due and payable was $43,552. The convertible notes were exchanged for 58,071 shares of the Company’s common stock. The effective exchange rate was $0.75 per share of the Company’s common stock. The closing price of the Company’s common stock on February 28, 2018, was $1.90 as reported by the OTC Markets. On February 28, 2018, the Board of Directors authorized the offering of a similar exchange arrangement at the same effective exchange rate of $0.75 per share of the Company’s common stock to all remaining holders of 10% Convertible Notes (some of which convertible notes are the subject of notices of default and therefore accruing annual interest at 12%); however, as of March 31, 2018, no other holders of convertible notes have elected to exchange their convertible notes on such terms. On May 31, 2018, the Company entered into exchange agreements with four holders of convertible notes who agreed to exchange their convertible notes for the Company’s common stock at an exchange rate of $0.75 per share. The note holders, in the aggregate, agreed to exchange $169,715 of principal and accrued interest for 226,288 shares of the Company’s common stock. The closing price of the Company’s common stock on May 31, 2018 was $0.92 per share. As a result of the exchange, $169,715 of convertible notes, inclusive of accrued interest, were cancelled and $208,185 market value of common stock was issued, resulting in a loss on extinguishment of debt of $38,470. As of June 30, 2018, principal and accrued interest on the remaining outstanding convertible note subject to a default notice totaled $36,772, of which $11,772 was accrued interest. As of December 31, 2017, principal and accrued interest on convertible notes subject to default notices totaled $91,028 of which $25,028 was accrued interest. As of June 30, 2018, the remaining outstanding convertible notes were convertible into 15,669 shares of the Company’s common stock, including 2,811 shares attributable to accrued interest of $53,205 payable as of such date. As of December 31, 2017, the outstanding convertible notes were convertible into 32,941 shares of the Company’s common stock, including 8,677 shares attributable to accrued interest of $98,646 payable as of such date. Such notes will continue to accrue interest until exchanged, if exchanged. If such notes are not exchanged, they will continue to accrue interest until either paid or otherwise discharged. There can be no assurance that any of the additional holders of the remaining 10% Convertible Notes will exchange their notes. Note Payable to SY Corporation Co., Ltd. On June 25, 2012, the Company borrowed 465,000,000 Won (the currency of South Korea, equivalent to approximately $400,000 United States Dollars) from and executed a secured note payable to SY Corporation Co., Ltd., formerly known as Samyang Optics Co. Ltd. (“SY Corporation”), an approximately 20% common stockholder of the Company at that time. SY Corporation was a significant stockholder and a related party at the time of the transaction but has not been a significant stockholder or related party of the Company subsequent to December 31, 2014. The note accrues simple interest at the rate of 12% per annum and had a maturity date of June 25, 2013. The Company has not made any payments on the promissory note. At June 30, 2013 and subsequently, the promissory note was outstanding and in default, although SY Corporation has not issued a notice of default or a demand for repayment. Management believes that SY Corporation is in default of its obligations under its January 2012 license agreement, as amended, with the Company, but the Company has not yet issued a notice of default. The Company has in the past made several efforts towards a comprehensive resolution of the aforementioned matters involving SY Corporation. During the six months ended June 30, 2018, there were no further communications between the Company and SY Corporation. The promissory note is secured by collateral that represents a lien on certain patents owned by the Company, including composition of matter patents for certain of the Company’s high impact ampakine compounds and the low impact ampakine compounds CX2007 and CX2076, and other related compounds. The security interest does not extend to the Company’s patents for its ampakine compounds CX717, CX1739 and CX1942, or to the patent for the use of ampakine compounds for the treatment of respiratory depression. Note payable to SY Corporation consists of the following at June 30, 2018 and December 31, 2017: June 30, 2018 December 31, 2017 Principal amount of note payable $ 399,774 $ 399,774 Accrued interest payable 291,124 267,335 Foreign currency transaction adjustment 28,284 (83,282 ) $ 719,182 $ 583,827 Interest expense with respect to this promissory note was $23,789 and $23,789 for the six months ended June 30, 2018 and 2017, respectively. Advances and Notes Payable to Officers On January 29, 2016, Dr. Arnold S. Lippa, the Company’s Chief Scientific Officer and Chairman of the Board of Directors, advanced $52,600 to the Company for working capital purposes under a demand promissory note with interest at 10% per annum. On September 23, 2016, Dr. Lippa advanced $25,000 to the Company for working capital purposes under a second demand promissory note with interest at 10% per annum. The notes are secured by the assets of the Company. Additionally, on April 9, 2018, Dr. Lippa advanced another $50,000 to the Company as discussed in more detail below. During the six months ended June 30, 2018 and 2017, $6,198 and $3,848 was charged to interest expense with respect to these notes, respectively. In connection with the loans, Dr. Lippa was issued fully vested warrants to purchase 15,464 shares of the Company’s common stock, 10,309 of which have an exercise price of $5.1025 per share and 5,155 of which have an exercise price of $4.85 which were the closing prices of the Company’s common stock on the respective dates of grant. The warrants expire on January 29, 2019 and September 23, 2019 respectively and may be exercised on a cashless basis. On February 2, 2016, Dr. James S. Manuso, the Company’s Chief Executive Officer and Vice Chairman of the Board of Directors, advanced $52,600 to the Company for working capital purposes under a demand promissory note with interest at 10% per annum. On September 22, 2016, Dr. Manuso, advanced $25,000 to the Company for working capital purposes under a demand promissory note with interest at 10% per annum. The notes are secured by the assets of the Company. Additionally, on April 9, 2018, Dr. Manuso advanced another $50,000 to the Company as discussed in more detail below. During the six months ended June 30, 2018 and 2017, $6,190 and $3,848 was charged to interest expense with respect to these notes, respectively. In connection with the loans, Dr. Manuso was issued fully vested warrants to purchase 13,092 shares of the Company’s common stock, 8,092 of which have an exercise price of $6.5000 per share and 5,000 of which have an exercise price of $5.00, which were the closing market prices of the Company’s common stock on the respective dates of grant. The warrants expire on February 2, 2019 and September 22, 2019, respectively, and may be exercised on a cashless basis. On April 9, 2018, Dr. Arnold S. Lippa and Dr. James S. Manuso, the Company’s Chief Scientific Officer and Chairman of the Board of Directors and the Company’s Chief Executive Officer and Vice Chairman of the Board of Directors, advanced $50,000 each, for a total of $100,000, to the Company for working capital purposes. Each note is payable on demand after June 30, 2018. Each note was subject to a mandatory exchange provision that provided that the principal amount of the note would be mandatorily exchanged into a board approved offering of the Company’s securities, if such offering held its first closing on or before June 30, 2018 and the amount of proceeds from such first closing was at least $150,000, not including the principal amounts of the notes that would be exchanged, or $250,000 including the principal amounts of such notes. Upon such exchange, the notes would be deemed repaid and terminated. Any accrued but unpaid interest outstanding at the time of such exchange will be (i) repaid to the note holder or (ii) invested in the offering, at the note holder’s election. A first closing did not occur on or before June 30, 2018. Dr. Arnold S. Lippa agreed to exchange his note into the board approved offering that had its initial closing on September 12, 2018 (See Note 9. Subsequent Events). Accrued interest on Dr. Lippa’s note did not exchange. Other Short-Term Notes Payable Other short-term notes payable at June 30, 2018 and December 31, 2017 consisted of premium financing agreements with respect to various insurance policies. At June 30, 2018, a premium financing agreement was payable in the initial amount of $63,750, with interest at 8.930% per annum, in ten monthly installments of $6,639. At June 30, 2018, the aggregate amount of the short-term notes payable was $49,272.

Settlement and Payments

Settlement and Payments	6 Months Ended
	Jun. 30, 2018
Settlement And Payments
Settlement and Payments	5. Settlement and Payments On April 5, 2018, the Company issued 185,388 common stock purchase options to Robert N. Weingarten, the Company’s former Chief Financial Officer and 125,000 common stock purchase options to Pharmaland Executive Consulting Services LLC (“Pharmaland”) exercisable until April 5, 2023 at $1.12 per share of common stock which was the closing price of the common stock as quoted on the OTC QB on that date. All of these common stock purchase options vested immediately. Each of the common stock purchase options were valued on the issuance date based upon a Black-Scholes valuation method at $1.081. The assumptions used for the Black Scholes calculation were a volatility of 186.07%, a risk-free rate of 2.64%, a zero dividend yield and a five year period to option maturity. Mr. Weingarten simultaneously with the issuance of the common stock purchase options, agreed to forgive $200,350 of accrued compensation owed to him. The value of the options granted to Mr. Weingarten was $200,404. The resulting loss on extinguishment of the accrued liability was $54. The common stock purchase options issued to Pharmaland was in partial payment of accounts payable owed. The common stock purchase options issued to Pharmaland had a value of $135,125 and the accounts payable paid was $124,025. The loss on extinguishment of this accounts payable was $11,100. The Company continues to explore ways to reduce its indebtedness, and might in the future enter additional settlements of potential claims or payments with respect to outstanding debts.

Stockholders' Deficiency

Stockholders' Deficiency	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Stockholders' Deficiency	6. Stockholders’ Deficiency Company has 70,000,000 authorized shares of stock, consisting of 65,000,000 shares designated as common stock, par value $0.001 per share, and 5,000,000 shares designated as preferred stock, par value $0.001 per share. As of June 30, 2018 and December 31, 2017, total stockholders’ deficiency was $5,069,128 and 4,355,384 respectively. Preferred Stock The Company has authorized a total of 5,000,000 shares of preferred stock, par value $0.001 per share. As of June 30, 2018 and December 31, 2017, 1,250,000 shares were designated as 9% Cumulative Convertible Preferred Stock (non-voting, “9% Preferred Stock”); 37,500 shares were designated as Series B Convertible Preferred Stock (non-voting, “Series B Preferred Stock”); 205,000 shares were designated as Series A Junior Participating Preferred Stock (non-voting, “Series A Junior Participating Preferred Stock”); and 1,700 shares were designated as Series G 1.5% Convertible Preferred Stock. Accordingly, as of June 30, 2018 and December 31, 2017, 3,505,800 shares of preferred stock were undesignated and may be issued with such rights and powers as the Board of Directors may designate. There were no shares of 9% Preferred Stock, Series A Junior Participating Preferred Stock, or Series G 1.5% Convertible Preferred Stock outstanding as of June 30, 2018 and December 31, 2017. Series B Preferred Stock outstanding as of June 30, 2018 and December 31, 2017 consisted of 37,500 shares issued in a May 1991 private placement. Each share of Series B Preferred Stock is convertible into approximately 0.00030 shares of common stock at an effective conversion price of $2,208.375 per share of common stock, which is subject to adjustment under certain circumstances. As of June 30, 2018 and December 31, 2017, the shares of Series B Preferred Stock outstanding are convertible into 11 shares of common stock. The Company may redeem the Series B Preferred Stock for $25,001, equivalent to $0.6667 per share of Series B Preferred Stock, an amount equal to its liquidation preference, at any time upon 30 days prior notice. Common Stock There are 3,349,620 shares of the Company’s Common Stock outstanding as of June 30, 2018. After reserving for conversions of convertible debt as well as common stock purchase options and warrants exercises, there are 53,044,573 shares of the Company’s Common Stock available for future issuances. 1 st On March 10, 2017 and March 28, 2017, the Company sold units to investors for aggregate gross proceeds of $350,000, with each unit consisting of one share of the Company’s common stock and one common stock purchase warrant to purchase one share of the Company’s common stock (the “1 st nd st On July 26, 2017, the Company’s Board approved an offering of securities conducted via private placement (the “2 nd nd st st nd st 2 nd On August 29, 2017, September 27, 2017, September 28, 2017, October 5, 2017, October 25, 2017, November 29, 2017, December 13, 2017, December 21, 2017, December 22, 2017 and December 29, 2017 the Company sold units in the 2 nd st nd nd nd The terms of the 2 nd nd st nd st nd st nd See Note 9 – Subsequent Events for a description of the 2018 Unit Offering. Common Stock Warrants A summary of warrant activity for the six months ended June 30, 2018 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding at December 31, 2017 1,464,415 $ 2.68146 4.88 Issued - - Warrants outstanding at June 30, 2018 1,464,415 $ 2.68146 4.29 Warrants exercisable at December 31, 2017 1,464,415 $ 2,68146 4.88 Warrants exercisable at June 30, 2018 1,464,415 $ 2.68146 4.29 The exercise prices of common stock warrants outstanding and exercisable are as follows at June 30, 2018: Exercise Price Warrants Outstanding (Shares) Warrants Exercisable (Shares) Expiration Date $ 1.0000 916,217 916,217 September 20, 2022 $ 1.2870 41,002 41,002 April 17, 2019 $ 1.5620 130,284 130,284 December 31, 2021 $ 2.7500 8,000 8000 September 20, 2022 $ 4.8500 5,155 5,155 September 23, 2019 $ 4.8750 108,594 108,594 September 30, 2020 $ 5.0000 5,000 5,000 September 22, 2019 $ 5.1025 10,309 10,309 January 29, 2019 $ 6.5000 8,092 8,092 February 4, 2019 $ 6.8348 145,758 145,758 September 30, 2020 $ 7.9300 86,004 86,004 February 28, 2021 1,464,415 1,464,415 Based on a fair market value of $1.00 per share on June 30, 2018, there were no exercisable in-the money common stock warrants as of June 30, 2018. A summary of warrant activity for the six months ended June 30, 2017 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding at December 31, 2016 540,198 $ 4.84842 3.93 Issued 148,000 2.75000 Warrants outstanding at June 30, 2017 688,198 $ 4.39715 3.67 Warrants exercisable at December 31, 2016 540,198 $ 4.84842 3.93 Warrants exercisable at June 30, 2017 688,198 $ 4.39715 3.67 The exercise prices of common stock warrants outstanding and exercisable were as follows at June 30, 2017: Exercise Price Warrants Outstanding (Shares) Warrants Exercisable (Shares) Expiration Date $ 1.2870 41,002 41,002 April 17, 2019 $ 1.5620 130,284 130,284 December 31, 2021 $ 4.8500 5,155 5,155 September 23, 2019 $ 4.8750 108,594 108,594 September 30, 2020 $ 5.0000 5,000 5,000 September 22, 2019 $ 5.1025 10,309 10,309 January 29, 2019 $ 6.5000 8,092 8,092 February 4, 2019 $ 6.8348 145,758 145,758 September 30, 2020 $ 7.9300 86,004 86,004 February 28, 2021 $ 2.7500 148,000 148,000 December 31, 2021 688,198 688,198 Based on a fair market value of $2.00 per share on June 30, 2017, the intrinsic value of exercisable in-the-money common stock warrants was $86,299 as of June 30, 2017. Stock Options On March 18, 2014, the stockholders of the Company holding a majority of the votes to be cast on the issue approved the adoption of the Company’s 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan (the “2014 Plan”), which had been previously adopted by the Board of Directors of the Company, subject to stockholder approval. The Plan permits the grant of options and restricted stock with respect to up to 325,025 shares of common stock, in addition to stock appreciation rights and phantom stock, to directors, officers, employees, consultants and other service providers of the Company. On June 30, 2015, the Board of Directors adopted the 2015 Stock and Stock Option Plan (the “2015 Plan”). The 2015 Plan initially provided for, among other things, the issuance of either or any combination of restricted shares of common stock and non-qualified stock options to purchase up to 461,538 shares of the Company’s common stock for periods up to ten years to management, members of the Board of Directors, consultants and advisors. The Company has not and does not intend to present the 2015 Plan to stockholders for approval. On August 18, 2015, the Board of Directors increased the number of shares that may be issued under the 2015 Plan to 769,231 shares of the Company’s common stock. On March 31, 2016, the Board of Directors further increased the number of shares that may be issued under the 2015 Plan to 1,538,461 shares of the Company’s common stock. On January 17, 2017, the Board of Directors further increased the number of shares that may be issued under the 2015 Plan to 3,038,461 shares of the Company’s common stock. On December 9, 2017, the Board of Directors further increased the number of shares that may be issued under the 2015 Plan to 6,985,260 shares of the Company’s common stock. Information with respect to the Black-Scholes variables used in connection with the evaluation of the fair value of stock-based compensation is provided at Note 3. A summary of stock option activity for the six months ended June 30, 2018 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Options outstanding at December 31, 2017 3,996,167 $ 3.7634 7.38 Granted 327,150 1.1267 4.75 Options outstanding at June 30, 2018 4,323,317 $ 3.5855 6.42 Options exercisable at December 31, 2017 3,996,167 $ 3.7634 7.38 Options exercisable at June 30, 2018 4,323,317 $ 3.5855 6.42 A summary of stock option activity for the six months ended June 30, 2017 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Options outstanding at December 31, 2016 1,307,749 $ 7.6515 Granted 680,000 3.1037 Options outstanding at June 30, 2017 1,987,749 $ 6.0957 5.00 Options exercisable at December 31, 2016 1,307,749 $ 7.6515 Options exercisable at June 30, 2017 1,987,749 $ 6.0957 5.00 There was no deferred compensation expense for outstanding and unvested stock options at either June 30, 2018 or December 31, 2017, respectively. The exercise prices of common stock options outstanding and exercisable were as follows at June 30, 2018: Exercise Price Options Outstanding (Shares) Options Exercisable (Shares) Expiration Date $ 1.1200 310,388 310,388 April 5, 2023 $ 1.2500 16,762 16,762 December 7, 2022 $ 1.3500 34,000 34,000 July 28, 2022 $ 1.4500 1,849,418 1,849,418 December 9, 2027 $ 1.4500 100,000 100,000 December 9, 2027 $ 2.0000 285,000 285,000 June 30, 2022 $ 2.0000 25,000 25,000 July 26, 2022 $ 3.9000 395,000 395,000 January 17, 2022 $ 4.5000 7,222 7,222 September 2, 2021 $ 5.6875 89,686 89,686 June 30, 2020 $ 5.7500 2,608 2,608 September 12, 2021 $ 6.4025 27,692 27,692 August 18, 2020 $ 6.4025 129,231 129,231 August 18, 2022 $ 6.4025 261,789 261,789 August 18, 2025 $ 6.8250 8,791 8,791 December 11, 2020 $ 7.3775 523,077 523,077 March 31, 2021 $ 8.1250 169,231 169,231 June 30, 2022 $ 13.0000 7,385 7,385 March 13, 2019 $ 13.0000 3,846 3,846 April 14, 2019 $ 13.9750 3,385 3,385 March 14, 2024 $ 15.4700 7,755 7,755 April 8, 2020 $ 15.9250 2,462 2,462 February 28, 2024 $ 16.0500 46,154 46,154 July 17, 2019 $ 16.6400 1,538 1,538 January 29, 2020 $ 19.5000 9,487 9,487 July 17, 2022 $ 19.5000 6,410 6,410 August 10, 2022 4,323,317 4,323,317 Based on a fair market value of $1.00 per share on June 30, 2018, there were no exercisable in-the-money common stock options as of June 30, 2018. The exercise prices of common stock options outstanding and exercisable were as follows at June 30, 2017: Exercise Price Options Outstanding (Shares) Options Exercisable (Shares) Expiration Date $ 2.0000 285,000 285,000 June 30, 2022 $ 3.9000 395,000 395,000 January 17, 2022 $ 4.5000 7,222 7,222 September 2, 2021 $ 5.6875 89,686 89,686 June 30, 2020 $ 5.7500 2,608 2,608 September 12, 2021 $ 6.4025 27,692 27,692 August 18, 2020 $ 6.4025 129,231 129,231 August 18, 2022 $ 6.4025 261,789 261,789 August 18, 2025 $ 6.8250 8,791 8,791 December 11, 2020 $ 7.3775 523,077 523,077 March 31, 2021 $ 8.1250 169,231 169,231 June 30, 2022 $ 13.0000 7,385 7,385 March 13, 2019 $ 13.0000 3,846 3,846 April 14, 2019 $ 13.9750 3,385 3,385 March 14, 2024 $ 15.4700 7,755 7,755 April 8, 2020 $ 15.9250 2,462 2,462 February 28, 2024 $ 16.0500 46,154 46,154 July 17, 2019 $ 16.6400 1,538 1,538 January 29, 2020 $ 19.5000 9,487 9,487 July 17, 2022 $ 19.5000 6,410 6,410 August 10, 2022 1,987,749 1,987,749 Based on a fair market value of $2.00 per share on June 30, 2017, there were no exercisable in-the-money common stock options as of June 30, 2017. For the six months ended June 30, 2018 and 2017, stock-based compensation costs included in the condensed consolidated statements of operations consisted of general and administrative expenses of $0 and $1,127,052, respectively, and research and development expenses of $0 and $595,201, respectively. Pier Contingent Stock Consideration In connection with the merger transaction with Pier effective August 10, 2012, RespireRx issued 179,747 newly issued shares of its common stock with an aggregate fair value of $3,271,402 ($18.2000 per share), based upon the closing price of RespireRx’s common stock on August 10, 2012. The shares of common stock were distributed to stockholders, convertible note holders, warrant holders, option holders, and certain employees and vendors of Pier in satisfaction of their interests and claims. The common stock issued by RespireRx represented approximately 41% of the 443,205 common shares outstanding immediately following the closing of the transaction. Pursuant to the terms of the transaction, RespireRx agreed to issue additional contingent consideration, consisting of up to 56,351 shares of common stock, to Pier’s former security holders and certain other creditors and service providers (the “Pier Stock Recipients”) that received RespireRx’s common stock as part of the Pier transaction if certain of RespireRx’s stock options and warrants outstanding immediately prior to the closing of the merger were subsequently exercised. In the event that such contingent shares were issued, the ownership percentage of the Pier Stock Recipients, following their receipt of such additional shares, could not exceed their ownership percentage as of the initial transaction date. The stock options and warrants outstanding at June 30, 2012 were all out-of-the-money on August 10, 2012. During late July and early August 2012, shortly before completion of the merger, the Company issued options to officers and directors at that time to purchase a total of 22,651 shares of common stock exercisable for ten years at $19.5000 per share. By October 1, 2012, these options, as well as the options and warrants outstanding at June 30, 2012, were also out-of-the-money and continued to be out-of-the-money through June 30, 2018. There were no stock options or warrants exercised subsequent to August 10, 2012 that triggered additional contingent consideration, and the only remaining stock options outstanding that could still trigger the additional contingent consideration remained out-of-the-money through June 30, 2018. As of June 30, 2018, due to the expirations and forfeitures of RespireRx stock options and warrants occurring since August 10, 2012, 6,497 contingent shares of common stock remained potentially issuable under the Pier merger agreement. The Company concluded that the issuance of any of the contingent shares to the Pier Stock Recipients was remote, as a result of the large spread between the exercise prices of these stock options and warrants as compared to the common stock trading range, the subsequent expiration or forfeiture of most of the options and warrants, the Company’s distressed financial condition and capital requirements, and that these stock options and warrants have remained significantly out-of-the-money through June 30, 2018. Accordingly, the Company considered the fair value of the contingent consideration to be immaterial and therefore did not ascribe any value to such contingent consideration. If any such shares are ultimately issued to the former Pier stockholders, the Company will recognize the fair value of such shares as a charge to operations at that time. Reserved and Unreserved Shares of Common Stock On January 17, 2017, the Board of Directors of the Company approved the adoption of an amendment of the Amended and Restated RespireRx Pharmaceuticals, Inc. 2015 Stock and Stock Option Plan (as amended, the “2015 Plan”). That amendment increases the shares issuable under the plan by 1,500,000, from 1,538,461 to 3,038,461. On December 9, 2017, the Board of Directors further amended the 2015 Plan to increase the number of shares that may be issued under the 2015 Plan to 6,985,260 shares of the Company’s common stock. Other than the change in the number of shares available under the 2015 Plan, no other changes were made to the 2015 Plan by these amendments. At June 30, 2018, the Company had 65,000,000 shares of common stock authorized and 3,349,620 shares of common stock issued and outstanding. Furthermore, as of June 30, 2018, the Company had reserved an aggregate of 11 shares for issuance upon conversion of the Series B Preferred Stock; 1,464,415 shares for issuance upon exercise of warrants; 4,323,317 shares for issuance upon exercise of outstanding stock options; 63,236 shares to cover equity grants available for future issuance pursuant to the 2014 Plan; 2,732,662 shares to cover equity grants available for future issuance pursuant to the 2015 Plan; 15,669 shares for issuance upon conversion of the Convertible Notes; and 6,497 shares issuable as contingent shares pursuant to the Pier merger. Accordingly, as of June 30, 2018, the Company had an aggregate of 8,605,807 shares of common stock reserved for issuance and 53,044,573 shares of common stock unreserved and available for future issuance. The Company expects to satisfy its future common stock commitments through the issuance of authorized but unissued shares of common stock.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions Dr. Arnold S. Lippa and Jeff E. Margolis, officers and directors of the Company since March 22, 2013, have indirect ownership interests and managing memberships in Aurora Capital LLC (“Aurora”) through interests held in its members, and Jeff. E. Margolis is also an officer of Aurora. Aurora is a boutique investment banking firm specializing in the life sciences sector that is also a full service brokerage firm. On March 31, 2013, the Company accrued $85,000 as reimbursement for legal fees incurred by Aurora in conjunction with the removal of the Company’s prior Board of Directors on March 22, 2013, which amount has been included in accounts payable and accrued expenses at June 30, 2018 and December 31, 2017. On June 30, 2015, the Board of Directors of the Company awarded, but did not pay, cash bonuses totaling $215,000, including an aggregate of $195,000 to certain of the Company’s executive officers and an aggregate of $20,000 to the independent members of the Company’s Board of Directors. The cash bonuses awarded to executive officers were as follows: Dr. Arnold S. Lippa - $75,000; Jeff E. Margolis - $60,000; and Robert N. Weingarten (resigned as an officer and director of the Company in February 2017, but remains a consultant to the Company) - $60,000. The cash bonuses awarded to the two independent members of the Company’s Board of Directors were as follows: James E. Sapirstein - $10,000; and Kathryn MacFarlane - $10,000. The cash bonuses were awarded as partial compensation for services rendered by such persons from January 1, 2015 through June 30, 2015. On June 30, 2015, the Board of Directors also established cash compensation arrangements for certain of the Company’s executive officers at the following monthly rates: Dr. Arnold S. Lippa - $12,500; Jeff E. Margolis - $10,000; and Robert N. Weingarten (resigned as an officer and director of the Company in February 2017, but remains a consultant to the Company) - $10,000. In addition, the Company established quarterly cash board fees for the two independent members of the Company’s Board of Directors as follows: James E. Sapirstein - $5,000; and Kathryn MacFarlane - $5,000. This compensation was payable in arrears and commenced on July 1, 2015. On August 18, 2015, the cash compensation arrangements for these executive officers were further revised as described below in Note 8. These new compensation arrangements have been extended through September 30, 2018. Both the cash bonuses and the cash monthly compensation were accrued and will not be paid in cash until such time as the Board of Directors of the Company determines that sufficient capital has been raised by the Company or is otherwise available to fund the Company’s operations on an ongoing basis. Such amounts of accrued compensation through September 30, 2017 were forgiven on December 9, 2017 when, on the same date certain amounts were granted as options, as further described below, and therefore such amounts are no longer included in accrued compensation and related expenses as of June 30, 2018 or December 31, 2017. Effective August 18, 2015, Company entered into employment agreements with Dr. Arnold S. Lippa, Robert N. Weingarten and Jeff E. Margolis, which superseded the compensation arrangements previously established for those officers on June 30, 2015, excluding the cash bonuses referred to above. On February 17, 2017, Robert N. Weingarten resigned as a director and as the Company’s Vice President and Chief Financial Officer, but remains a consultant to the Company. Jeff E. Margolis’ employment agreement was amended effective July 1, 2017. The employment agreement amendment called for payment in three installments in cash of the $60,000 bonus granted on June 30, 2015. A minimum of $15,000 was to be payable in cash as follows: (a) $15,000 payable in cash upon the next closing (after July 1, 2017) of any financing in excess of $100,000 (b) $15,000 payable by the end of the following month assuming cumulative closings (beginning with the closing that triggered (a)) in excess of $200,000 and (c) $30,000 payable in cash upon the next closing of any financing in excess of an additional $250,000. The conditions of (a), (b) and (c) above were met as of December 31, 2017, however Mr. Margolis has waived the Company’s obligation to make any payments of the cash bonus until the Board of Directors of the Company determines that sufficient capital has been raised by the Company or is otherwise available to fund the Company’s operations on an ongoing basis. Obligations through September 30, 2017 were forgiven by Mr. Margolis as described below. On March 28, 2017, Aurora earned $20,000 of cash fees and 8,000 placement agent common stock warrants associated with the closing of 1 st On December 9, 2017, the Company accepted offers from Dr. Arnold S. Lippa, Dr. James S. Manuso, Jeff E. Margolis, James E. Sapirstein, Kathryn MacFarlane and Robert N. Weingarten (former Chief Financial Officer) pursuant to which such individuals would forgive accrued compensation and related accrued expenses as of September 30, 2017 in the following amounts: $807,497; $878,360; $560,876; $55,000; $55,000 and $200,350 respectively for a total of $2,557,083. On the same date, the Company granted to the same individuals, or designees of such individuals from the 2015 Plan, non-qualified stock options, exercisable for 10 years with an exercise price of $1.45 per share of common stock, among other terms and features as follows: 559,595; 608,704; 388,687; 38114; 38,114 and 138,842 respectively, for options exercisable into a total of 1,772,055 shares of common stock with a total value of $2,475,561. As a result of his resignation in February 2017, Mr. Weingarten is no longer considered a related party of the Company as of June 30, 2018. A description of advances and notes payable to officers is provided at Note 4.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Pending or Threatened Legal Action and Claims By letter dated May 18, 2018, the Company received notice from counsel claiming to represent TEC Edmonton and The Governors of the University of Alberta, which purports to terminate, effective December 12, 2017, the license agreement dated May 9, 2007 between the Company and The Governors of the University of Alberta. The Company, through its counsel, disputed any grounds for termination and notified the representative that it invoked Section 13 of that license agreement, which mandates a meeting to be attended by individuals with decision-making authority to attempt in good faith to negotiate a resolution to the dispute. The Company is in discussions with TEC Edmonton to determine whether and under what conditions a resolution to the dispute can be reached and the parties have extended the applicable deadlines under the license agreement to continue those discussions, but a resolution has not yet been reached. No assurance can be provided that the parties will reach an acceptable resolution and, in light of the early stages of the disagreement, we cannot estimate the possible impact of this disagreement on the Company’s operations or business prospects. By e-mail dated July 21, 2016, the Company received a demand from an investment banking consulting firm that represented the Company in 2012 in conjunction with the Pier transaction alleging that $225,000 is due and owing for unpaid investment banking services rendered. Such amount has been accrued at June 30, 2018 and December 31, 2017. By letter dated February 5, 2016, the Company received a demand from a law firm representing a professional services vendor of the Company alleging an amount due and owing for unpaid services rendered. On January 18, 2017, following an arbitration proceeding, an arbitrator awarded the vendor the full amount sought in arbitration of $146,082. Additionally, the arbitrator granted the vendor attorneys’ fees and costs of $47,937. All such amounts have been accrued at June 30, 2018 and December 31, 2017. The Company is periodically the subject of various pending and threatened legal actions and claims. In the opinion of management of the Company, adequate provision has been made in the Company’s consolidated financial statements at June 30, 2018, December 31, 2017 and June 30, 2017 with respect to such matters, including, specifically, the matters noted above. The Company intends to vigorously defend itself if any of the matters described above results in the filing of a lawsuit or formal claim. Significant Agreements and Contracts Consulting Agreement Richard Purcell, the Company’s Senior Vice President of Research and Development since October 15, 2014, provides his services to the Company on a month-to-month basis through his consulting firm, DNA Healthlink, Inc., through which the Company has contracted for his services, for a monthly cash fee of $12,500. Additional information with respect to shares of common stock that have been issued to Mr. Purcell is provided at Note 6. Cash compensation expense pursuant to this agreement totaled $37,500 for the three months ended June 30, 2018 and 2017 and $75,000 for the six months ended June 30, 2018 and 2017, which is included in research and development expenses in the Company’s condensed consolidated statements of operations for such periods. Employment Agreements On August 18, 2015, the Company entered into an employment agreement with Dr. James S. Manuso, Ph.D., to be its new President and Chief Executive Officer. Dr. Manuso resigned as President and Chief Executive Officer effective September 30, 2018 (See 9. Subsequent Events) and therefore Dr. Manuso’s employment agreement was not automatically extended as described below. Pursuant to the agreement, which was for an initial term through September 30, 2018 (and which would have been deemed to be automatically extended, upon the same terms and conditions, for successive periods of one year, unless either party provided written notice of its intention not to extend the term of the agreement at least 90 days prior to the applicable renewal date, except that Dr. Manuso resigned effective September 30, 2018), Dr. Manuso received an annual base salary of $375,000. Dr. Manuso was, through September 30, 2018, also eligible to earn a performance-based annual bonus award of up to 50% of his base salary, based upon the achievement of annual performance goals established by the Board of Directors in consultation with the executive prior to the start of such fiscal year, or any amount at the discretion of the Board of Directors. No such bonuses were earned or granted during the three and six month periods ended June 30, 2018 and June 30, 2017. Additionally, Dr. Manuso was granted stock options to acquire 261,789 shares of common stock of the Company and was eligible to receive additional awards under the Company’s Plans in the discretion of the Board of Directors. No such awards were granted to Dr. Manuso granted during the three and six month periods ended June 30, 2018 and June 30, 2017. Dr. Manuso was also entitled to receive, until such time as the Company established a group health plan for its employees, $1,200 per month, on a tax-equalized basis, as additional compensation to cover the cost of health coverage and up to $1,000 per month, on a tax-equalized basis, as additional compensation for a term life insurance policy and disability insurance policy. Such amounts were accrued for the three and six month periods ended June 30, 2018 and June 30, 2017. Dr. Manuso was also entitled to be reimbursed for business expenses. The Company has accrued all submitted and approved business expenses as of June 30, 2018, December 30, 2017 and June 30, 2017. Additional information with respect to the stock options granted to Dr. Manuso is provided at Note 6. Cash compensation accrued pursuant to this agreement totaled $103,650 for each of the three months ended June, 2018, and 2017, respectively and $207,300 for the six months ended June 30, 2018 and 2017, respectively. Such amounts were included in accrued compensation and related expenses in the Company’s condensed consolidated balance sheet at June 30, 2018 and 2017, respectively, and in general and administrative expenses in the Company’s consolidated statement of operations for the three and six months ended June 30, 2018 and 2017, as appropriate. On December 9, 2017, Dr. Manuso forgave $878,360 of accrued compensation and related expenses which was the amount owed by the Company as of September 30, 2017, as described in more detail below. On the same date, Dr. Manuso received options to purchase 608,704 shares of common stock, as described in more detail below. Dr. Manuso did not receive any additional compensation for serving as Vice Chairman or a member of on the Board of Directors. Amounts accruing after September 30, 2017 have not been paid to Dr. Manuso. Effective on September 30, 2018, Dr. Manuso also resigned as Vice Chairman and as a member of the Board of Directors (See Note 9. Subsequent Events). On August 18, 2015, concurrently with the hiring of Dr. James S. Manuso as the Company’s new President and Chief Executive Officer, Dr. Arnold S. Lippa resigned as the Company’s President and Chief Executive Officer. On October 12, 2018, Dr. Lippa was named Interim President and Interim Chief Executive Officer (see Note 9. Subsequent Events) to replace Dr. Manuso who resigned effective September 30, 2018. Dr. Lippa continues to serve as the Company’s Executive Chairman and as a member of the Board of Directors. Also on August 18, 2015, Dr. Lippa was named Chief Scientific Officer of the Company, and the Company entered into an employment agreement with Dr. Lippa in that capacity. Pursuant to the agreement, which is for an initial term through September 30, 2018 (and which will be deemed to be automatically extended, upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term of the agreement at least 90 days prior to the applicable renewal date), Dr. Lippa received an annual base salary of $300,000. Dr. Lippa is also eligible to earn a performance-based annual bonus award of up to 50% of his base salary, based upon the achievement of annual performance goals established by the Board of Directors in consultation with the executive prior to the start of such fiscal year, or any amount at the discretion of the Board of Directors. Additionally, Dr. Lippa was granted stock options to acquire 30,769 shares of common stock of the Company and is eligible to receive additional awards under the Company’s Plans at the discretion of the Board of Directors. Dr. Lippa is also entitled to receive, until such time as the Company establishes a group health plan for its employees, $1,200 per month, on a tax-equalized basis, as additional compensation to cover the cost of health coverage and up to $1,000 per month, on a tax-equalized basis, as reimbursement for a term life insurance policy and disability insurance policy. Dr. Lippa is also entitled to be reimbursed for business expenses. Additional information with respect to the stock options granted to Dr. Lippa is provided at Note 6. Cash compensation accrued pursuant to this agreement totaled $84,900 for each of the three months ended June 30, 2018 and 2017, respectively, and $169,800 for the six months ended June 30, 2018 and 2017, respectively, which amounts are included in accrued compensation and related expenses in the Company’s consolidated balance sheet at June 30, 2018 and December 31, 2017, and in research and development expenses in the Company’s consolidated statement of operations. Cash compensation accrued to Dr. Lippa for bonuses and under a prior superseded arrangement, while still serving as the Company’s President and Chief Executive Officer, totaled $94,758 and was part of the amount forgiven on December 9, 2017 and therefore is no longer included in accrued compensation and related expenses as of June 30, 2018 and December 31, 2017. Dr. Lippa does not receive any additional compensation for serving as Executive Chairman and on the Board of Directors. On December 9, 2017, Dr. Lippa forgave $807,497 of accrued compensation and related expenses which was the amount owed by the Company as of September 30, 2017. On the same date, Dr. Lippa received options to purchase 559,595 shares of common stock, as described in more detail below. On August 18, 2015, the Company also entered into an employment agreement with Jeff E. Margolis, in his continuing role as Vice President, Secretary and Treasurer. Pursuant to the agreement, which was for an initial term through September 30, 2016 (and which will be deemed to be automatically extended upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term of the agreement at least 90 days prior to the applicable renewal date), Mr. Margolis received an annual base salary of $195,000, and is also eligible to receive performance-based annual bonus awards ranging from $65,000 to $125,000, based upon the achievement of annual performance goals established by the Board of Directors in consultation with the executive prior to the start of such fiscal year, or any amount at the discretion of the Board of Directors. Additionally, Mr. Margolis was granted stock options to acquire 30,769 shares of common stock of the Company and is eligible to receive additional awards under the Company’s Plans at the discretion of the Board of Directors. Mr. Margolis is also entitled to receive, until such time as the Company establishes a group health plan for its employees, $1,200 per month, on a tax-equalized basis, as additional compensation to cover the cost of health coverage and up to $1,000 per month, on a tax-equalized basis, as reimbursement for a term life insurance policy and disability insurance policy. Mr. Margolis is also each entitled to be reimbursed for business expenses. Additional information with respect to the stock options granted to Mr. Margolis is provided at Note 6. Jeff E. Margolis’ employment agreement was amended effective July 1, 2017. The employment agreement amendment called for payment in three installments in cash of the $60,000 bonus granted on June 30, 2015. A minimum of $15,000 was to be payable in cash as follows: (a) $15,000 payable in cash upon the next closing (after July 1, 2017) of any financing in excess of $100,000 (b) $15,000 payable by the end of the following month assuming cumulative closings (beginning with the closing that triggered (a)) in excess of $200,000 and (c) $30,000 payable in cash upon the next closing of any financing in excess of an additional $250,000. The conditions of (a), (b) and (c) above were met as of December 31, 2017, however Mr. Margolis has waived the Company’s obligation to make any payments of the cash bonus until the Board of Directors of the Company determines that sufficient capital has been raised by the Company or is otherwise available to fund the Company’s operations on an ongoing basis. The employment agreements between the Company and each of Dr. Manuso, Dr. Lippa, and Mr. Margolis, respectively, provided that the payment obligations associated with the first year base salary were to accrue, but no payments were to be made, until at least $2,000,000 of net proceeds from any offering or financing of debt or equity, or a combination thereof, was received by the Company, at which time scheduled payments were to commence. As this financing milestone has not been achieved, Dr. Manuso, Dr. Lippa, and Mr. Margolis (who are each also directors of the Company) have each agreed, effective as of August 11, 2016, to continue to defer the payment of such amounts indefinitely, until such time as the Board of Directors of the Company determines that sufficient capital has been raised by the Company or is otherwise available to fund the Company’s operations on an ongoing basis. On December 9, 2017, the Company accepted offers from Dr. Arnold S. Lippa, Dr. James S. Manuso, Jeff E. Margolis, James E. Sapirstein, Kathryn MacFarlane and Robert N. Weingarten (former Chief Financial Officer) pursuant to which such individuals would forgive accrued compensation and related accrued expenses as of September 30, 2017 in the following amounts: $807,497, $878,360, $560,876, $55,000, $55,000, and $200,350, respectively, for a total of $2,557,083. On the same date, the Company granted to the same individuals, or designees of such individuals from the 2015 Plan, non-qualified stock options, exercisable for 10 years with an exercise price of $1.45 per share of common stock, among other terms and features as follows: 559,595, 608,704, 388,687, 38114, 38,114, and 138,842, respectively, for options exercisable into a total of 1,772,055 shares of common stock with a total value of $2,475,561. University of California, Irvine License Agreements The Company entered into a series of license agreements in 1993 and 1998 with the University of California, Irvine (“UCI”) that granted the Company proprietary rights to certain chemical compounds that acted as ampakines and to their therapeutic uses. These agreements granted the Company, among other provisions, exclusive rights: (i) to practice certain patents and patent applications, as defined in the license agreement, that were then held by UCI; (ii) to identify, develop, make, have made, import, export, lease, sell, have sold or offer for sale any related licensed products; and (iii) to grant sub-licenses of the rights granted in the license agreements, subject to the provisions of the license agreements. The Company was required, among other terms and conditions, to pay UCI a license fee, royalties, patent costs and certain additional payments. On April 15, 2013, the Company received a letter from UCI indicating that the license agreements between UCI and the Company had been terminated due to the Company’s failure to make certain payments required to maintain the agreements. Since the patents covered in these license agreements had begun to expire and the therapeutic uses described in these patents were no longer germane to the Company’s new focus on respiratory disorders, the loss of these license agreements is not expected to have a material impact on the Company’s current drug development programs. In the opinion of management, the Company has made adequate provision for any liability relating to this matter in its consolidated financial statements at June 30, 2018 and December 31, 2017. University of Alberta License Agreement On May 9, 2007, the Company entered into a license agreement, as amended, with the University of Alberta granting the Company exclusive rights to practice patents held by the University of Alberta claiming the use of ampakines for the treatment of various respiratory disorders. The Company agreed to pay the University of Alberta a licensing fee and a patent issuance fee, which were paid, and prospective payments consisting of a royalty on net sales, sublicense fee payments, maintenance payments and milestone payments. The prospective maintenance payments commence on the enrollment of the first patient into the first Phase 2B clinical trial and increase upon the successful completion of the Phase 2B clinical trial. As the Company does not at this time anticipate scheduling a Phase 2B clinical trial in the near term, no maintenance payments to the University of Alberta are currently due and payable, nor are any maintenance payments expected to be due in the near future in connection with the license agreement. On May 18, 2018, the Company received a letter from counsel claiming to represent TEC Edmonton and The Governors of the University of Alberta, which purports to terminate, effective December 12, 2017, the license agreement dated May 9, 2007 (as subsequently amended) between the Company and The Governors of the University of Alberta. The Company, through its counsel, disputed any grounds for termination and notified the representative that it invoked Section 13 of that license agreement, which mandates a meeting to be attended by individuals with decision-making authority to attempt in good faith to negotiate a resolution to the dispute. The Company is in discussions with TEC Edmonton to determine whether and under what conditions a resolution to the dispute can be reached and the parties have extended the applicable deadlines under the license agreement to continue those discussions. No assurance can be provided that the parties will reach an acceptable resolution and, in light of the early stages of the disagreement, we cannot estimate the possible impact of this disagreement on the Company’s operations or business prospects. See Note 9. Subsequent Events. Transactions with Biovail Laboratories International SRL In March 2010, the Company entered into an asset purchase agreement with Biovail Laboratories International SRL (“Biovail”). Pursuant to the asset purchase agreement, Biovail acquired the Company’s interests in CX717, CX1763, CX1942 and the injectable dosage form of CX1739, as well as certain of its other ampakine compounds and related intellectual property for use in the field of respiratory depression or vaso-occlusive crises associated with sickle cell disease. The agreement provided the Company with the right to receive milestone payments in an aggregate amount of up to $15,000,000 plus the reimbursement of certain related expenses, conditioned upon the occurrence of particular events relating to the clinical development of certain assets that Biovail acquired. None of these events occurred. As part of the transaction, Biovail licensed back to the Company certain exclusive and irrevocable rights to some acquired ampakine compounds, other than CX717, an injectable dosage form of CX1739, CX1763 and CX1942, for use outside of the field of respiratory depression or vaso-occlusive crises associated with sickle cell disease. Accordingly, following the transaction with Biovail, the Company retained its rights to develop and commercialize the non-acquired ampakine compounds as a potential treatment for neurological diseases and psychiatric disorders. Additionally, the Company retained its rights to develop and commercialize the ampakine compounds as a potential treatment for sleep apnea disorders, including an oral dosage form of ampakine CX1739. In September 2010, Biovail’s parent corporation, Biovail Corporation, combined with Valeant Pharmaceuticals International in a merger transaction and the combined company was renamed “Valeant Pharmaceuticals International, Inc.” (“Valeant”). Following the merger, Valeant and Biovail conducted a strategic and financial review of their product pipeline and, as a result, in November 2010, Biovail announced its intent to exit from the respiratory depression project acquired from the Company in March 2010. Following that announcement, the Company entered into discussions with Biovail regarding the future of the respiratory depression project. In March 2011, the Company entered into a new agreement with Biovail to reacquire the ampakine compounds, patents and rights that Biovail had acquired from the Company in March 2010. The new agreement provided for potential future payments of up to $15,150,000 by the Company based upon the achievement of certain developments, including new drug application submissions and approval milestones. Biovail is also eligible to receive additional payments of up to $15,000,000 from the Company based upon the Company’s net sales of an intravenous dosage form of the compounds for respiratory depression. At any time following the completion of Phase 1 clinical studies and prior to the end of Phase 2A clinical studies, Biovail retains an option to co-develop and co-market intravenous dosage forms of an ampakine compound as a treatment for respiratory depression and vaso-occlusive crises associated with sickle cell disease. In such an event, the Company would be reimbursed for certain development expenses to date and Biovail would share in all such future development costs with the Company. If Biovail makes the co-marketing election, the Company would owe no further milestone payments to Biovail and the Company would be eligible to receive a royalty on net sales of the compound by Biovail or its affiliates and licensees. University of Illinois 2014 Exclusive License Agreement On June 27, 2014, the Company entered into an Exclusive License Agreement (the “2014 License Agreement”) with the University of Illinois, the material terms of which were similar to a License Agreement between the parties that had been previously terminated on March 21, 2013. The 2014 License Agreement became effective on September 18, 2014, upon the completion of certain conditions set forth in the 2014 License Agreement, including: (i) the payment by the Company of a $25,000 licensing fee, (ii) the payment by the Company of outstanding patent costs aggregating $15,840, and (iii) the assignment to the University of Illinois of rights the Company held in certain patent applications, all of which conditions were fulfilled. The 2014 License Agreement granted the Company (i) exclusive rights to several issued and pending patents in numerous jurisdictions and (ii) the non-exclusive right to certain technical information that is generated by the University of Illinois in connection with certain clinical trials as specified in the 2014 License Agreement, all of which relate to the use of cannabinoids for the treatment of sleep related breathing disorders. The Company is developing dronabinol (Δ9-tetrahydrocannabinol), a cannabinoid, for the treatment of OSA, the most common form of sleep apnea. The 2014 License Agreement provides for various commercialization and reporting requirements commencing on June 30, 2015 and also requires the Company to pay the University of Illinois a license fee, royalties, patent costs and certain milestone payments. The 2014 License Agreement provides for various royalty payments by the Company, including a royalty on net sales of 4%, payment on sub-licensee revenues of 12.5%, and a minimum annual royalty of $100,000 beginning in 2015, which is due and payable on December 31 of each year. The 2017 minimum annual royalty of $100,000 was paid as scheduled in December 2017. In the year after the first application for market approval is submitted to the FDA and until approval is obtained, the minimum annual royalty will increase to $150,000. In the year after the first market approval is obtained from the FDA and until the first sale of a product, the minimum annual royalty payable by the Company will increase to $200,000. In the year after the first commercial sale of a product, the minimum annual royalty will increase to $250,000. The 2014 License Agreement also provides for certain one-time milestone payments by the Company. A payment of $75,000 is due within five days after any one of the following: (a) dosing of the first patient with a product in a Phase 2 human clinical study anywhere in the world that is not sponsored by the University of Illinois, (b) dosing of the first patient in a Phase 2 human clinical study anywhere in the world with a low dose of dronabinol, or (c) dosing of the first patient in a Phase 1 human clinical study anywhere in the world with a proprietary reformulation of dronabinol. A payment of $350,000 is due within five days after dosing of the first patient with a product in a Phase 3 human clinical trial anywhere in the world. A payment of $500,000 is due within five days after the first new drug application filing with the FDA or a foreign equivalent for a product. A payment of $1,000,000 is due within 12 months after the first commercial sale of a product. During the three and six months ended June 30, 2018 and 2017, the Company recorded charges to operations of $25,000 and $50,000, respectively, with respect to its 2018 and 2017 minimum annual royalty obligation, which is included in research and development expenses in the Company’s condensed consolidated statement of operations for the three and six months ended June 30, 2018 and 2017. Research Contract with the University of Alberta On January 12, 2016, the Company entered into a Research Contract with the University of Alberta in order to test the efficacy of ampakines at a variety of dosage and formulation levels in the potential treatment of Pompe Disease, apnea of prematurity and spinal cord injury, as well as to conduct certain electrophysiological studies to explore the ampakine mechanism of action for central respiratory depression. The Company agreed to pay the University of Alberta total consideration of approximately CAD$146,000 (approximately US$111,000), consisting of approximately CAD$85,000 (approximately US$65,000) of personnel funding in cash in four installments during 2016, to provide approximately CAD$21,000 (approximately US$16,000) in equipment, to pay patent costs of CAD$20,000 (approximately US$15,000), and to underwrite additional budgeted costs of CAD$20,000 (approximately US$15,000). As of December 31, 2017, the Company had recorded final amounts payable in respect to this Research Contract of US$16,207 (CAD$21,222) which amount was paid in US dollars in January 2018 and completed the payments under the contract. The conversion to US dollars above utilizes an exchange rate of approximately US$0.76 for every CAD$1.00. The University of Alberta received matching funds through a grant from the Canadian Institutes of Health Research in support of this research. The Company retained the rights to research results and any patentable intellectual property generated by the research. Dr. John Greer, faculty member of the Department of Physiology, Perinatal Research Centre and Women & Children’s Health Research Institute at the University of Alberta collaborated on this research. The studies were completed in 2016. See “University of Alberta License Agreement” above for more information on the related license agreement. National Institute of Drug Abuse Agreement As a result of agreements entered into on October 19, 2015 and January 19, 2016, the Medications Development Program of the National Institute of Drug Abuse (“NIDA”) funded and conducted research on the Company’s ampakine compounds CX717 and CX1739 to determine their potential usefulness for the treatment of cocaine and methamphetamine addiction and abuse. The Company retains all intellectual property resulting from this research, as well as proprietary and commercialization rights to these compounds. In general, the ampakines did not produce behavioral effects in rats and mice that are commonly associated with administration of stimulants such as cocaine or amphetamines. Instead, the ampakines reduced the stimulation produced by both of these drugs. In addition, the ampakines were not recognized as cocaine- or amphetamine-like when administered to rats that had been trained to recognize whether they had been administered these drugs. The absence of stimulant properties on the part of the ampakines may confirm their value as potential non-stimulant treatments for ADHD. Duke University Clinical Trial Agreement On January 27, 2015, the Company entered into a Clinical Study and Research Agreement with Duke University (as amended, the “Duke Agreement”) to develop and conduct a protocol for a program of clinical study and research which was amended on October 30, 2015 and further amended on July 28, 2016, which agreement, as amended, resulted in a total amount payable under the Agreement to $678,327. During the six months ended June 30, 2018 and 2017, the Company charged $0 to research and development expenses with respect to work conducted pursuant to the Duke Agreement. The clinical trial completed in October 2016 and the Company announced the study results on December 15, 2016. Amounts still owing under this agreement are in the Company’s balance sheets at June 30, 2018 and December 31, 2017 Sharp Clinical Services, Inc. Agreement The Company has various agreements with Sharp Clinical Services, Inc. to provide packaging, labeling, distribution and analytical services. Covance Laboratories Inc. Agreement On October 26, 2016, the Company entered into a twelve month agreement with Covance Laboratories Inc. to provide compound testing and storage services with respect to CX1739, CX1866 and CX1929 at a total budgeted cost of $35,958. This agreement was renewed in October 2017. Summary of Principal Cash Obligations and Commitments The following table sets forth the Company’s principal cash obligations and commitments for the next five fiscal years as of June 30, 2018, aggregating $1,380,150. Amounts included in the 2018 column represent amounts contractually due at June 30, 2018 during the remainder of the 2018 fiscal year ending December 31, 2018. Payments Due By Year Total 2018 2019 2020 2021 2022 Research and development contracts $ - $ - $ - $ - $ - $ - Clinical trial agreements - - - - - - License agreements 450,000 50,000 100,000 100,000 100,000 100,000 Employment and consulting agreements (1) 930,150 434,250 495,900 - - - Total $ 1,380,150 $ 484,250 $ 595,900 $ 100,000 $ 100,000 $ 100,000 (1) The payment of such amounts has been deferred indefinitely, as described above at “Employment Agreements”. Does not include amounts after September 30, 2018 for Dr. Manuso as his resignation was effective on such date. 2018 obligationsinclude six months of employment agreement obligations for Dr. Lippa and Mr. Margolis as their employment contracts renewed on September 30, 2018 (See Note 9. Subsequent Events) and 2019 obligations include nine months of obligations through September 30, 2019.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	9. Subsequent Events The Company performed an evaluation of subsequent events through the date of filing these financial statements with the SEC. There were no material subsequent events which affected, or could affect, the amounts or disclosures in the condensed consolidated financial statements, other than those discussed below. Resignation of James S. Manuso, President and Chief Executive Officer, Vice Chairman and Member of the Board of Directors The resignation of Dr. James S. Manuso as the Company’s President and Chief Executive Officer, Vice Chairman and member of the Board of Directors became effective on September 30, 2018, the end of the term of his employment agreement. Dr. Manuso did not resign because of any disagreement with the Company relating to the Company’s operations, policies or practices. Dronabinol Development and Supply Agreement On September 4, 2018, RespireRx entered into a dronabinol Development and Supply Agreement with Noramco Inc., one of the world’s major dronabinol manufacturers. Under the terms of the Agreement, Noramco agreed to (i) provide all of the active pharmaceutical ingredient (“API”) estimated to be needed for the clinical development process for both the first- and second-generation products (each a “Product” and collectively, the “Products”), three validation batches for NDA filing(s) and adequate supply for the initial inventory stocking for the wholesale and retail channels, subject to certain limitations, (ii) maintain or file valid drug master files (“DMFs”) with the FDA or any other regulatory authority and provide the Company with access or a right of reference letter entitling the Company to make continuing reference to the DMFs during the term of the agreement in connection with any regulatory filings made with the FDA by the Company, (iii) participate on a development committee, and (iv) make available its regulatory consultants, collaborate with any regulatory consulting firms engaged by the Company and participate in all FDA or Drug Enforcement Agency (“DEA”) meetings as appropriate and as related to the API. In consideration for these supplies and services, the Company has agreed to purchase exclusively from Noramco during the commercialization phase all API for its Products at a pre-determined price subject to certain producer price adjustments, and agreed to Noramco’s participation in the economic success of the commercialized Product or Products up to the earlier of the achievement of a maximum dollar amount or the expiration of a period of time. 2018 Unit Offering On September 12, 2018, the Company consummated an initial closing on an offering (“2018 Unit Offering”) of Units comprised of one share of the Company’s common stock and one common stock purchase warrant. The 2018 Unit Offering may be up to $1.5 million and has a final closing date of October 15, 2018. The initial closing was for $250,750 of which $200,750 was the gross cash proceeds. The additional $50,000 was represented by the conversion or exchange into the 2018 Unit Offering of the principal amount of the Arnold S. Lippa, Demand Promissory Note described below. Units were sold for $1.05 per unit and the warrants issued in connection with the units are exercisable through April 30, 2023 at a fixed price of 150% of the unit purchase price. The warrants contain a cashless exercise provision and certain blocker provisions preventing exercise if the investor would beneficially own more than 4.99% of the Company’s outstanding shares of common stock as a result of such exercise. The warrants are also subject to redemption by the Company at $0.001 per share upon ten (10) days written notice if the Company’s common stock closes at $3.00 or more for any five (5) consecutive trading days. In total, 238,814 shares of the Company’s common stock and 238,814 common stock purchase warrants were purchased. Other than Arnold S. Lippa, the investors in the offering were not affiliates of the Company. Investors also received an unlimited number of piggy-back registration rights in respect to the shares of common stock and the shares of common stock underlying the common stock purchase warrants, unless such common stock is eligible to be sold with volume limits under an exemption from registration under any rule or regulation of the SEC that permits the holder to sell securities of the Company to the public without registration and without volume limits (assuming the holder is not an affiliate). The shares of common stock and common stock purchase warrants were offered and sold without registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as provided in Rule 506(b) of Regulation D promulgated thereunder. None of the shares of common stock issued as part of the units, the common stock purchase warrants, the Common Stock issuable upon exercise of the common stock purchase warrants or any warrants issued to a qualified referral source (of which there were none in the initial closing) have been registered under the Securities Act or any other applicable securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. Prior to the initial closing of the 2018 Unit Offering, the Company issued to Arnold S. Lippa, Ph.D, and James S. Manuso, Ph.D., the Company’s Executive Chairman and Chief Scientific Officer and Vice Chairman and Chief Executive Officer, respectively, $100,000 aggregate principal amount ($50,000 each) of demand promissory notes bearing interest at 10% (the “Demand Promissory Notes”). The Demand Promissory Note issued to Dr. Lippa, exclusive of any interest accrued, was exchanged or converted into the 2018 Unit Offering simultaneously with its initial closing. The principal amount of, but not the interest on, the Demand Promissory Note was taken into consideration when determining if the Company had achieved the minimum amount necessary to effect the initial closing of the 2018 Unit Offering. The Demand Promissory Note issued to Dr. Manuso was not exchanged or converted in connection with the initial closing of the 2018 Unit Offering, but the Company currently anticipates that it will be exchanged or converted in connection with a future closing of the 2018 Unit Offering or a subsequent offering. In addition, as set forth in the Purchase Agreements, each Purchaser has an unlimited number of exchange rights, which are options and not obligations, to exchange such Purchaser’s entire investment (but not less than the entire investment) into one or more subsequent equity financings (consisting solely of convertible preferred stock or common stock or units containing preferred stock or common stock and warrants exercisable only into preferred stock or common stock) that would be considered as “permanent equity” under United States Generally Accepted Accounting Principles and the rules and regulations of the United States Securities and Exchange Commission, and therefore classified within stockholders’ equity, and excluding any form of debt or convertible debt or preferred stock redeemable at the discretion of the holder (each such financing a “Subsequent Equity Financing”). These exchange rights are effective until the earlier of: (i) the completion of any number of Subsequent Equity Financings that aggregate at least $15 million of gross proceeds, or (ii) December 30, 2018. For clarity, a Purchaser’s entire investment is the entire amount invested (“Investment Amount”) (for purposes of the multiple described below) and all of the Common Stock and Warrants purchased (for purposes of the exchange) pursuant to the Purchase Agreement of such Purchaser, however, if the Warrants have been exercised in part or in whole on a cashless basis, then the Investment Amount (for purposes of the multiple described below) will be the Investment Amount (for purposes of the multiple described below) and all of the Common Stock initially purchased pursuant to the Purchase Agreement of such Purchaser plus any shares of Common Stock issued pursuant to a cashless exercise and any Warrants remaining after such cashless exercise (for purposes of the exchange), or, if the Warrants have been exercised for cash, then the entire investment will be the Investment Amount plus the amount of cash paid upon cash exercise (for purposes of the multiple described below) and all of the Common Stock initially purchased pursuant to the Purchase Agreement of such Purchaser plus any shares of Common Stock issued pursuant to the cash exercise and any Warrants remaining after such cash exercise (for purposes of the exchange).

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of RespireRx and its wholly-owned subsidiary, Pier. Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high quality financial institutions. The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid short-term investments with maturities of less than three months when acquired to be cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The authoritative guidance with respect to fair value of financial instruments established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The carrying amounts of financial instruments (consisting of cash, cash equivalents, advances on research grants and accounts payable and accrued expenses) are considered by the Company to be representative of the respective fair values of these instruments due to the short-term nature of those instruments. With respect to the note payable to SY Corporation and the convertible notes payable, management does not believe that the credit markets have materially changed for these types of borrowings since the original borrowing date. The Company considers the carrying amounts of the notes payable to officers, inclusive of accrued interest, to be representative of the respective fair values of such instruments due to the short-term nature of those instruments and their terms.
Deferred Financing Costs	Deferred Financing Costs Costs incurred in connection with ongoing debt and equity financings, including legal fees, are deferred until the related financing is either completed or abandoned. Costs related to abandoned debt or equity financings are charged to operations in the period of abandonment. Costs related to completed debt financings are presented as a direct deduction from the carrying amount of the related debt liability (see “Capitalized Financing Costs” below). Costs related to completed equity financings are charged directly to additional paid-in capital.
Capitalized Financing Costs	Capitalized Financing Costs The Company presents debt issuance costs related to debt liability in its condensed consolidated balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with the presentation for debt discounts.
Convertible Notes Payable	Convertible Notes Payable Original Issuance of Notes and Warrants Convertible notes are evaluated to determine if they should be recorded at amortized cost. To the extent that there are associated warrants, the convertible notes and warrants are evaluated to determine if there are embedded derivatives to be identified, bifurcated and valued at fair value in connection with and at the time of such financing. 2018 Notes Exchange In cases where debt or other liabilities are exchanged for equity, the Company compares the value of debt, inclusive of accrued interest, if applicable, being exchanged for equity to the value of the equity issued and records any loss or gain as a result of such exchange. See Note 4. Notes Payable.
Extinguishment of Debt	Extinguishment of Debt The Company accounts for the extinguishment of debt in accordance with GAAP by comparing the carrying value of the debt to the fair value of consideration paid or assets given up and recognizing a loss or gain in the condensed consolidated statement of operations in the amount of the difference in the period in which such transaction occurs.
Equipment	Equipment Equipment is recorded at cost and depreciated on a straight-line basis over their estimated useful lives, which range from three to five years. All equipment was fully depreciated as of June 30, 2018.
Long-Term Prepaid Insurance	Long-Term Prepaid Insurance Long-term prepaid insurance represents the premium paid in March 2017 for directors’ and officers’ insurance tail coverage, which is being amortized on a straight-line basis over the policy period of six years. The amount amortizable in the ensuing twelve-month period is recorded as a current asset in the Company’s condensed consolidated balance sheet at each reporting date.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews its long-lived assets, including long-term prepaid insurance, for impairment whenever events or changes in circumstances indicate that the total amount of an asset may not be recoverable, but at least annually. An impairment loss is recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than the asset’s carrying amount. The Company has not deemed any long-lived assets as impaired at June 30, 2018.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues common stock and stock options to officers, directors, Scientific Advisory Board members, consultants and other vendors for services rendered. Such issuances vest and expire according to terms established at the issuance date of each grant. The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards. The Company accounts for stock-based payments to Scientific Advisory Board members, consultants and other vendors by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached, or (b) at the date at which the necessary performance to earn the equity instruments is complete. Stock grants, which are generally subject to time-based vesting, are measured at the grant date fair value and charged to operations ratably over the vesting period. Stock options granted to members of the Company’s Scientific Advisory Board, outside consultants and other vendors are revalued each reporting period until vested to determine the amount to be recorded as an expense in the respective period. As the stock options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the value on the date of vesting. The fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock. Stock options and warrants issued to non-employees as compensation for services to be provided to the Company or in settlement of debt are accounted for based upon the fair value of the services provided or the estimated fair value of the stock option or warrant, whichever can be more clearly determined. Management uses the Black-Scholes option-pricing model to determine the fair value of the stock options and warrants issued by the Company. The Company recognizes this expense over the period in which the services are provided. For stock options requiring an assessment of value during the six months ended June 30, 2018, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model using the following assumptions: Risk-free interest rate 2.64-2.68 % Expected dividend yield 0 % Expected volatility 186.00 to 190.55 % Expected life in years 4.52 to 5.00 For stock options requiring an assessment of value during the six months ended June 30, 2017, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model using the following assumptions: Risk-free interest rate 1.89 % Expected dividend yield 0 % Expected volatility 140.00 % Expected life 3.4 to 5 years The Company recognizes the fair value of stock-based compensation in general and administrative costs and in research and development costs, as appropriate, in the Company’s condensed consolidated statements of operations. The Company issues new shares of common stock to satisfy stock option and warrant exercises. There were no stock options exercised during the six months ended June 30, 2018 and 2017. There were no warrants issued in the six months ended June 30, 2018 and 2017 requiring such assessment.
Income Taxes	Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The Company may have had a change in control under these Sections. However, the Company does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss and tax credit carryforwards until the time that it anticipates it will be able to utilize these tax attributes. As of June 30, 2018, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of June 30, 2018, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.
Foreign Currency Transactions	Foreign Currency Transactions The note payable to SY Corporation, which is denominated in a foreign currency (the South Korean Won), is translated into the Company’s functional currency (the United States Dollar) at the exchange rate on the balance sheet date. The foreign currency exchange gain or loss resulting from translation is recognized in the related condensed consolidated statements of operations.
Research and Development	Research and Development Research and development costs include compensation paid to management directing the Company’s research and development activities, and fees paid to consultants and outside service providers and organizations (including research institutes at universities), and other expenses relating to the acquisition, design, development and clinical testing of the Company’s treatments and product candidates. Research and development costs incurred by the Company under research grants are expensed as incurred over the life of the underlying contracts, unless the terms of the contract indicate that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis. On May 6, 2016, the Company made an advance payment to Duke University with respect to the Phase 2A clinical trial of CX1739. At June 30, 2018, an asset balance of $48,912 remained from the advance payment.
License Agreements	License Agreements Obligations incurred with respect to mandatory payments provided for in license agreements are recognized ratably over the appropriate period, as specified in the underlying license agreement, and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Obligations incurred with respect to milestone payments provided for in license agreements are recognized when it is probable that such milestone will be reached and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Payments of such liabilities are made in the ordinary course of business.
Patent Costs	Patent Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred.
Earnings Per Share	Earnings per Share The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Net income (loss) attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed preferred stock dividends declared, amortized or accumulated. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive. At June 30, 2018 and 2017, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. June, 2018 2017 Series B convertible preferred stock 11 11 Convertible notes payable 15,669 31,398 Common stock warrants 1,464,415 688,198 Common stock options 4,323,317 1,987,749 Total 5,803,412 2,707,356
Reclassifications	Reclassifications Certain comparative figures in 2017 have been reclassified to conform to the current quarter’s presentation. These reclassifications were immaterial, both individually and in the aggregate.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Summary of Fair Value of Option Estimated Using Black-Scholes Pricing Model with Valuation Assumptions	For stock options requiring an assessment of value during the six months ended June 30, 2018, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model using the following assumptions: Risk-free interest rate 2.64-2.68 % Expected dividend yield 0 % Expected volatility 186.00 to 190.55 % Expected life in years 4.52 to 5.00 For stock options requiring an assessment of value during the six months ended June 30, 2017, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model using the following assumptions: Risk-free interest rate 1.89 % Expected dividend yield 0 % Expected volatility 140.00 % Expected life 3.4 to 5 years
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	At June 30, 2018 and 2017, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. June, 2018 2017 Series B convertible preferred stock 11 11 Convertible notes payable 15,669 31,398 Common stock warrants 1,464,415 688,198 Common stock options 4,323,317 1,987,749 Total 5,803,412 2,707,356

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Schedule of Notes Payable	The convertible notes (including those for which default notices have been received) consist of the following at June 30, 2018 and December 31, 2017: June 30, 2018 December 31, 2017 Principal amount of notes payable $ 125,000 $ 276,000 Add accrued interest payable 53,205 98,646 $ 178,205 $ 374,646
Summary of Note Payable to Related Party	Note payable to SY Corporation consists of the following at June 30, 2018 and December 31, 2017: June 30, 2018 December 31, 2017 Principal amount of note payable $ 399,774 $ 399,774 Accrued interest payable 291,124 267,335 Foreign currency transaction adjustment 28,284 (83,282 ) $ 719,182 $ 583,827

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Schedule of Warrants Activity	A summary of warrant activity for the six months ended June 30, 2018 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding at December 31, 2017 1,464,415 $ 2.68146 4.88 Issued - - Warrants outstanding at June 30, 2018 1,464,415 $ 2.68146 4.29 Warrants exercisable at December 31, 2017 1,464,415 $ 2,68146 4.88 Warrants exercisable at June 30, 2018 1,464,415 $ 2.68146 4.29 A summary of warrant activity for the six months ended June 30, 2017 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding at December 31, 2016 540,198 $ 4.84842 3.93 Issued 148,000 2.75000 Warrants outstanding at June 30, 2017 688,198 $ 4.39715 3.67 Warrants exercisable at December 31, 2016 540,198 $ 4.84842 3.93 Warrants exercisable at June 30, 2017 688,198 $ 4.39715 3.67
Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable	The exercise prices of common stock warrants outstanding and exercisable are as follows at June 30, 2018: Exercise Price Warrants Outstanding (Shares) Warrants Exercisable (Shares) Expiration Date $ 1.0000 916,217 916,217 September 20, 2022 $ 1.2870 41,002 41,002 April 17, 2019 $ 1.5620 130,284 130,284 December 31, 2021 $ 2.7500 8,000 8000 September 20, 2022 $ 4.8500 5,155 5,155 September 23, 2019 $ 4.8750 108,594 108,594 September 30, 2020 $ 5.0000 5,000 5,000 September 22, 2019 $ 5.1025 10,309 10,309 January 29, 2019 $ 6.5000 8,092 8,092 February 4, 2019 $ 6.8348 145,758 145,758 September 30, 2020 $ 7.9300 86,004 86,004 February 28, 2021 1,464,415 1,464,415 The exercise prices of common stock warrants outstanding and exercisable were as follows at June 30, 2017: Exercise Price Warrants Outstanding (Shares) Warrants Exercisable (Shares) Expiration Date $ 1.2870 41,002 41,002 April 17, 2019 $ 1.5620 130,284 130,284 December 31, 2021 $ 4.8500 5,155 5,155 September 23, 2019 $ 4.8750 108,594 108,594 September 30, 2020 $ 5.0000 5,000 5,000 September 22, 2019 $ 5.1025 10,309 10,309 January 29, 2019 $ 6.5000 8,092 8,092 February 4, 2019 $ 6.8348 145,758 145,758 September 30, 2020 $ 7.9300 86,004 86,004 February 28, 2021 $ 2.7500 148,000 148,000 December 31, 2021 688,198 688,198
Schedule of Stock Options Activity	A summary of stock option activity for the six months ended June 30, 2018 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Options outstanding at December 31, 2017 3,996,167 $ 3.7634 7.38 Granted 327,150 1.1267 4.75 Options outstanding at June 30, 2018 4,323,317 $ 3.5855 6.42 Options exercisable at December 31, 2017 3,996,167 $ 3.7634 7.38 Options exercisable at June 30, 2018 4,323,317 $ 3.5855 6.42 A summary of stock option activity for the six months ended June 30, 2017 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Options outstanding at December 31, 2016 1,307,749 $ 7.6515 Granted 680,000 3.1037 Options outstanding at June 30, 2017 1,987,749 $ 6.0957 5.00 Options exercisable at December 31, 2016 1,307,749 $ 7.6515 Options exercisable at June 30, 2017 1,987,749 $ 6.0957 5.00
Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable	The exercise prices of common stock options outstanding and exercisable were as follows at June 30, 2018: Exercise Price Options Outstanding (Shares) Options Exercisable (Shares) Expiration Date $ 1.1200 310,388 310,388 April 5, 2023 $ 1.2500 16,762 16,762 December 7, 2022 $ 1.3500 34,000 34,000 July 28, 2022 $ 1.4500 1,849,418 1,849,418 December 9, 2027 $ 1.4500 100,000 100,000 December 9, 2027 $ 2.0000 285,000 285,000 June 30, 2022 $ 2.0000 25,000 25,000 July 26, 2022 $ 3.9000 395,000 395,000 January 17, 2022 $ 4.5000 7,222 7,222 September 2, 2021 $ 5.6875 89,686 89,686 June 30, 2020 $ 5.7500 2,608 2,608 September 12, 2021 $ 6.4025 27,692 27,692 August 18, 2020 $ 6.4025 129,231 129,231 August 18, 2022 $ 6.4025 261,789 261,789 August 18, 2025 $ 6.8250 8,791 8,791 December 11, 2020 $ 7.3775 523,077 523,077 March 31, 2021 $ 8.1250 169,231 169,231 June 30, 2022 $ 13.0000 7,385 7,385 March 13, 2019 $ 13.0000 3,846 3,846 April 14, 2019 $ 13.9750 3,385 3,385 March 14, 2024 $ 15.4700 7,755 7,755 April 8, 2020 $ 15.9250 2,462 2,462 February 28, 2024 $ 16.0500 46,154 46,154 July 17, 2019 $ 16.6400 1,538 1,538 January 29, 2020 $ 19.5000 9,487 9,487 July 17, 2022 $ 19.5000 6,410 6,410 August 10, 2022 4,323,317 4,323,317 The exercise prices of common stock options outstanding and exercisable were as follows at June 30, 2017: Exercise Price Options Outstanding (Shares) Options Exercisable (Shares) Expiration Date $ 2.0000 285,000 285,000 June 30, 2022 $ 3.9000 395,000 395,000 January 17, 2022 $ 4.5000 7,222 7,222 September 2, 2021 $ 5.6875 89,686 89,686 June 30, 2020 $ 5.7500 2,608 2,608 September 12, 2021 $ 6.4025 27,692 27,692 August 18, 2020 $ 6.4025 129,231 129,231 August 18, 2022 $ 6.4025 261,789 261,789 August 18, 2025 $ 6.8250 8,791 8,791 December 11, 2020 $ 7.3775 523,077 523,077 March 31, 2021 $ 8.1250 169,231 169,231 June 30, 2022 $ 13.0000 7,385 7,385 March 13, 2019 $ 13.0000 3,846 3,846 April 14, 2019 $ 13.9750 3,385 3,385 March 14, 2024 $ 15.4700 7,755 7,755 April 8, 2020 $ 15.9250 2,462 2,462 February 28, 2024 $ 16.0500 46,154 46,154 July 17, 2019 $ 16.6400 1,538 1,538 January 29, 2020 $ 19.5000 9,487 9,487 July 17, 2022 $ 19.5000 6,410 6,410 August 10, 2022 1,987,749 1,987,749

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Summary of Principal Cash Obligations and Commitments	Payments Due By Year Total 2018 2019 2020 2021 2022 Research and development contracts $ - $ - $ - $ - $ - $ - Clinical trial agreements - - - - - - License agreements 450,000 50,000 100,000 100,000 100,000 100,000 Employment and consulting agreements (1) 930,150 434,250 495,900 - - - Total $ 1,380,150 $ 484,250 $ 595,900 $ 100,000 $ 100,000 $ 100,000 (1) The payment of such amounts has been deferred indefinitely, as described above at “Employment Agreements”. Does not include amounts after September 30, 2018 for Dr. Manuso as his resignation was effective on such date. 2018 obligationsinclude six months of employment agreement obligations for Dr. Lippa and Mr. Margolis as their employment contracts renewed on September 30, 2018 (See Note 9. Subsequent Events) and 2019 obligations include nine months of obligations through September 30, 2019.

Business (Details Narrative)

Business (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net losses	$ 635,363	$ 1,584,066	$ 1,382,042	$ 3,053,212	$ 4,291,483
Negative operating cash flows			184,028	$ 456,393	697,009
Stockholders' deficiency	$ 5,069,128		$ 5,069,128		$ 4,355,384

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017
Advance payment on research contract	$ 48,912	$ 48,912	$ 48,912
Minimum [Member]
Estimated useful lives of equipment	P3Y
Maximum [Member]
Estimated useful lives of equipment	P5Y

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Fair Value of Option Estimated Using Black-Scholes Pricing Model with Valuation Assumptions (Details)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Risk-free interest rate		1.89%
Expected dividend yield	0.00%	0.00%
Expected volatility		140.00%
Minimum [Member]
Risk-free interest rate	2.64%
Expected volatility	186.00%
Expected life in years	4 years 6 months 7 days	3 years 4 months 24 days
Maximum [Member]
Risk-free interest rate	2.68%
Expected volatility	190.55%
Expected life in years	5 years	5 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share	5,803,412	2,707,356
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	1,464,415	688,198
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	4,323,317	1,987,749
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	15,669	31,398
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	11	11

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	May 31, 2018	Feb. 28, 2018	Feb. 02, 2016	Jan. 29, 2016	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Apr. 09, 2018	Apr. 05, 2018	Sep. 23, 2016	Sep. 22, 2016	Dec. 31, 2015	Dec. 31, 2014	Aug. 10, 2012	Jun. 25, 2012
Debt instrument interest rate					8.93%		8.93%
Common stock closing price, per share											$ 1.12					$ 18.2000
Loss on extinguishment of debt					$ (49,625)		$ (105,253)
Converted into common stock							15,669
Stockholder's percentage																	20.00%
Percentage of convertible notes payable																	12.00%
Interest expense					33,795	$ 26,283	$ 61,068	51,321
Insurance premium					63,750		63,750
Short term borrowings					49,272		49,272
Ten Monthly Installments [Member]
Debt periodic payments							6,639
SY Corporation [Member]
Interest expense							23,789	23,789
SY Corporation [Member] | Won [Member]
Convertible notes payable aggregate amount																	$ 465,000,000
SY Corporation [Member] | US Dollars [Member]
Convertible notes payable aggregate amount																	$ 400,000
Exchange Agreement [Member]
Convertible notes payable aggregate amount	$ 169,715	$ 43,552
Number of exchanged for common stock shares	169,715	58,071
Common stock exchange rate per share	$ 0.75	$ 0.75
Common stock closing price, per share	$ 0.92	$ 1.90
Debt instrument default interest rate per year		12.00%
Accrued interest	$ 226,288
Market value of common stock on exchange	208,185
Loss on extinguishment of debt	$ 38,470
Board of Directors [Member] | Exchange Agreement [Member]
Debt instrument interest rate		10.00%
Common stock exchange rate per share		$ 0.75
Dr. Lippa [Member]
Percentage of convertible notes payable				10.00%								10.00%
Advances total				$ 52,600						$ 50,000		$ 25,000
Interest expense							$ 6,198	3,848
Issuance of fully vested warrant to purchase shares of common stock				15,464
Dr. Lippa [Member] | Share-based Compensation Award, Tranche One [Member]
Warrant to purchase shares				10,309
Warrants, exercise price				$ 5.1025
Dr. Lippa [Member] | Tranche Two [Member]
Warrant to purchase shares				5,155
Warrants, exercise price				$ 4.85
Dr. Arnold S.Lippa [Member]
Advances total										50,000
Warrants expires date description							The warrant expires on January 29, 2019 and September 23, 2019.
Dr. James S. Manuso [Member]
Percentage of convertible notes payable			10.00%
Advances total			$ 52,600							50,000
Interest expense							$ 6,190	$ 3,848
Issuance of fully vested warrant to purchase shares of common stock			13,092
Dr. James S. Manuso [Member] | Share-based Compensation Award, Tranche One [Member]
Warrant to purchase shares			8,092
Warrants, exercise price			$ 6.5000
Dr. James S. Manuso [Member] | Tranche Two [Member]
Warrant to purchase shares			5,000
Warrants, exercise price			$ 5
Dr. Manuso [Member]
Percentage of convertible notes payable													10.00%
Advances total										50,000			$ 25,000
Four Officer [Member]
Warrants expires date description							The warrants expire on February 2, 2019 and September 22, 2019
Dr. Arnold S. Lippa and Dr. James S. Manuso [Member]
Convertible notes payable aggregate amount					250,000		$ 250,000
Advances total										$ 100,000
Closing value of common stock					$ 150,000		$ 150,000
Convertible Notes Payable [Member]
Debt instrument interest rate					10.00%		10.00%
Warrant to purchase shares					27,936		27,936
Extended maturity date							Sep. 15, 2016
Warrants, exercise price					$ 11.375		$ 11.375
Convertible Notes Payable [Member] | Minimum [Member] | October 3, 2016 and October 25, 2016
Debt instrument interest rate					10.00%		10.00%
Convertible Notes Payable [Member] | Maximum [Member] | October 3, 2016 and October 25, 2016
Debt instrument interest rate					12.00%		12.00%
Convertible Notes Payable [Member] | Investor [Member]
Convertible notes payable aggregate amount														$ 579,500	$ 579,500
Debt instrument interest rate														10.00%	10.00%
Shares issued price per share														$ 11.3750	$ 11.3750
Warrant to purchase shares														50,945	50,945
Warrants exercisable fixed price per share														$ 11.3750	$ 11.3750
Two Convertible Notes [Member]
Debt periodic payments		$ 66,782
Convertible Notes [Member]
Debt instrument interest rate									10.00%
Debt periodic payments							$ 36,772		$ 91,028
Accrued interest					$ 11,772		11,772		25,028
Notes Payable [Member]
Accrued interest					$ 53,205		$ 53,205		$ 98,646
Converted into common stock							15,669		32,941
Number of conversion into common shares attributable to accrued interest							2,811		8,677

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Convertible notes payable, gross	$ 178,205	$ 374,646
Notes Payable [Member]
Principal amount of notes payable	125,000	276,000
Add accrued interest payable	53,205	98,646
Convertible notes payable, gross	$ 178,205	$ 374,646

Notes Payable - Summary of Note

Notes Payable - Summary of Note Payable to Related Party (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Total note payable	$ 719,181	$ 583,827
SY Corporation [Member]
Principal amount of note payable	399,774	399,774
Accrued interest payable	291,124	267,335
Foreign currency transaction adjustment	28,284	(83,282)
Total note payable	$ 719,182	$ 583,827

Settlement and Payments (Detail

Settlement and Payments (Details Narrative) - USD ($)	Apr. 05, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Aug. 10, 2012
Common stock purchase options				327,150	680,000
Stock option exercisable date	Apr. 5, 2023
Common stock closing price, per share	$ 1.12					$ 18.2000
Stock options valuation amount	$ 1.081
Loss on extinguishment of debt		$ (49,625)		$ (105,253)
Common stock options issued	$ 135,125
Accounts payable paid	124,025
Accrued Liability [Member]
Loss on extinguishment of debt	54
Accounts Payable [Member]
Loss on extinguishment of debt	$ 11,100
Valuation Technique, Option Pricing Model [Member] | Volatility [Member]
Fair value assumptions, measurement input, percentages	18607.00%
Valuation Technique, Option Pricing Model [Member] | Risk-Free Rate [Member]
Fair value assumptions, measurement input, percentages	2.64%
Valuation Technique, Option Pricing Model [Member] | Expected Dividend Rate [Member]
Fair value assumptions, measurement input, percentages	0.00%
Valuation Technique, Option Pricing Model [Member] | Expected Term [Member]
Fair value assumptions, measurement input, term	5 years
Robert N. Weingarten [Member]
Common stock purchase options	185,388
Accrued compensation	$ 200,350
Value of options granted	$ 200,404
Pharmaland Executive Consulting Services LLC [Member]
Common stock purchase options	125,000

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative) - USD ($)	Dec. 29, 2017	Dec. 22, 2017	Dec. 21, 2017	Dec. 13, 2017	Dec. 09, 2017	Dec. 09, 2017	Nov. 29, 2017	Oct. 25, 2017	Oct. 05, 2017	Sep. 28, 2017	Sep. 27, 2017	Aug. 29, 2017	Mar. 28, 2017	Mar. 10, 2017	Jan. 17, 2017	Mar. 31, 2016	Aug. 18, 2015	Jun. 30, 2015	Mar. 18, 2014	Aug. 10, 2012	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Apr. 05, 2018	Dec. 31, 2016
Common stock, shares authorized																					65,000,000		65,000,000
Common stock, shares designated																					65,000,000
Common stock, par value																					$ 0.001		$ 0.001
Preferred stock, shares designated																					5,000,000
Preferred stock, par value																					$ 0.001
Stockholders' deficiency																					$ 5,069,128		$ 4,355,384
Preferred stock, shares authorized																					5,000,000
Preferred stock voting																					Cumulative Convertible Preferred Stock (non-voting, “9% Preferred Stock”)
Common stock, shares outstanding																				443,205	3,349,619		3,065,261
Common stock available for future issuances																					8,605,807
Purchase price per share																				$ 18.2000				$ 1.12
Fair value of market price per share																					$ 1	$ 2
Stock warrant intrinsic value of exercisable																						$ 86,299
Share granted during period																					327,150	680,000
Common stock fixed price per shares																					$ 1	$ 2
Stock-based compensation expense						$ 2,557,083
Sold units for aggregate cash consideration																				179,747
Fair value of common stock																				$ 3,271,402
Percentage of common stock issued																				41.00%
Issue additional contingent consideration																				56,351
Common stock, shares issued																					3,349,619		3,065,261
Number of warrants, outstanding, exercisable																					1,464,415	688,198	1,464,415		540,198
Debt instrument conversion into shares																					15,669
Number of common stock shares unreserved for future issuance																					53,044,573
Minimum [Member]
Stock option period																					4 years 6 months 7 days	3 years 4 months 24 days
Maximum [Member]
Stock option period																					5 years	5 years
Pier Merger Agreement [Member]
Issuance of contingent shares of common stock																					6,497
General and Administrative Expense [Member]
Stock-based compensation expense																					$ 0	$ 1,127,052
Research and Development Member [Member]
Stock-based compensation expense																					$ 0	$ 595,201
2014 Equity Plan [Member]
Share granted during period																			325,025
Board of Directors [Member]
Preferred stock, shares undesignated																					3,505,800		3,505,800
Board of Directors [Member] | 2015 Stock and Stock Option Plan [Member]
Option issued to purchase number of common stock																		461,538
Stock option period																		10 years
Board of Directors [Member] | 2015 Equity Plan [Member]
Share granted during period					6,985,260										3,038,461	1,538,461	769,231
Board of Directors [Member] | 2015 Stock and Stock Option Plan [Member]
Share granted during period															1,500,000
Board of Directors [Member] | 2015 Stock and Stock Option Plan [Member] | Minimum [Member]
Share granted during period															1,538,461
Board of Directors [Member] | 2015 Stock and Stock Option Plan [Member] | Maximum [Member]
Share granted during period															3,038,461
Board of Directors [Member] | 2015 Stock and Stock Option Plan [Member]
Share granted during period					6,985,260
Officer and Director [Member]
Share granted during period																				22,651
Stock options exercise price																				$ 19.5000
Series B Convertible Preferred Stock [Member]
Preferred stock, shares designated																					37,500		37,500
Preferred stock, par value																					$ 0.001		$ 0.001
Stockholders' deficiency																					$ (21,703)		$ (21,703)
Preferred stock, shares authorized																					37,500		37,500
Preferred stock shares issuable upon conversion, per share																					$ 0.00030		$ 0.00030
Debt instrument, conversion price per share																					$ 2,208.375		$ 2,208.375
Preferred stock shares issuable upon conversion																					11		11
Preferred stock redemption amount																					$ 25,001		$ 25,001
Redeemed preferred stock price per share																					$ 0.6667		$ 0.6667
Preferred stock conversion into common stock description																					Each share of Series B Preferred Stock is convertible into approximately 0.00030 shares of common stock at an effective conversion price of $2,208.375 per share of common stock, which is subject to adjustment under certain circumstances.		Each share of Series B Preferred Stock is convertible into approximately 0.00030 shares of common stock at an effective conversion price of $2,208.375 per share of common stock, which is subject to adjustment under certain circumstances.
Series B Convertible Preferred Stock [Member] | Stock Option [Member]
Conversion of stock																					4,323,317
Series B Convertible Preferred Stock [Member] | 2014 Plan [Member]
Common stock available for future issuances																					63,236
Series B Convertible Preferred Stock [Member] | 2015 Plan [Member]
Common stock available for future issuances																					2,732,662
Series A Junior Participating Preferred Stock [Member]
Preferred stock, shares designated																					205,000		205,000
Series G 1.5% Convertible Preferred Stock [Member]
Preferred stock, shares designated																					1,700		1,700
9% Cumulative Convertible Preferred Stock [Member]
Preferred stock, shares designated																					1,250,000		1,250,000
Common Stock [Member]
Stockholders' deficiency																					$ (3,350)		$ (3,065)
Common stock, shares outstanding																					3,349,620
Common stock available for future issuances																					53,044,573
1st 2017 Unit Offering [Member] | Aurora Capital LLC [Member]
Cash placement agent fees																					$ 20,000
Number of warrant shares fee																					8,000
Additional paid in capital warrants																					$ 27,648
1st 2017 Unit Offering [Member] | Investors [Member]
Common stock, par value																					$ 0.001
Gross proceeds													$ 350,000	$ 350,000							$ 15,000,000
Purchase price per share																					$ 2.50
Warrant exercisable date																					Dec. 31, 2021
Warrants, exercise price																					$ 2.75
Percentage of investor beneficially outstanding shares of common stock																					4.99%
Percentage of unit purchase price																					200.00%
1st 2017 Unit Offering [Member] | Subsequent Equity Financing [Member]
Purchase price per share													$ 3.80	$ 4.05
2nd 2017 Unit Offering [Member] | Investors [Member]
Common stock, par value																					$ 0.001
Gross proceeds	$ 404,500	$ 404,500	$ 404,500	$ 404,500			$ 404,500	$ 404,500	$ 404,500	$ 404,500	$ 404,500	$ 404,500									$ 15,000,000
Purchase price per share	$ 1.14	$ 1.45	$ 1.51	$ 1.45			$ 1.05	$ 0.80	$ 1.50	$ 1.40	$ 1.40	$ 1									$ 1
Warrant exercisable date																					Sep. 29, 2022
Warrants, exercise price																					$ 1.10
Percentage of investor beneficially outstanding shares of common stock																					4.99%
Percentage of unit purchase price																					250.00%
Warrants description																					The warrants are also subject to redemption by the Company at $0.001 per share upon ten (10) days written notice if the Company's common stock closes at 250% or more of the unit purchase price for any five (5) consecutive trading days.

Stockholders' Deficiency - Sche

Stockholders' Deficiency - Schedule of Warrants Activity (Details) - $ / shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Equity [Abstract]
Number of Warrants, Outstanding, Beginning balance	1,464,415	540,198
Number of Warrants, Outstanding, Exercisable, Beginning balance	1,464,415	540,198
Number of Warrants, Issued		148,000
Number of Warrants, Outstanding, Ending balance	1,464,415	688,198
Number of Warrants, Outstanding, Exercisable Ending balance	1,464,415	688,198
Weighted Average Exercise Price, Outstanding, Beginning	$ 2.68146	$ 4.84842
Weighted Average Exercise Price, Exercisable Beginning	2.68146	4.84842
Weighted Average Exercise Price, Issued		2.75000
Weighted Average Exercise Price, Outstanding, Ending	2.68146	4.39715
Weighted Average Exercise Price, Exercisable, Ending	$ 2.68146	$ 4.39715
Warrants outstanding ,Weighted Average Remaining Contractual Life (in Years), Beginning	4 years 10 months 17 days	3 years 11 months 4 days
Warrants exercisable, Weighted Average Remaining Contractual Life (in Years), Beginning	4 years 10 months 17 days	3 years 11 months 4 days
Warrants outstanding ,Weighted Average Remaining Contractual Life (in Years), Ending	4 years 3 months 15 days	3 years 8 months 2 days
Warrants exercisable, Weighted Average Remaining Contractual Life (in Years), Ending	4 years 3 months 15 days	3 years 8 months 2 days

Stockholders' Deficiency - Sc_2

Stockholders' Deficiency - Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable (Details) - $ / shares	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Warrants, Outstanding (Shares)	1,464,415	1,464,415	688,198	540,198
Warrants, Exercisable (Shares)	1,464,415	1,464,415	688,198	540,198
Warrants [Member]
Warrants, Outstanding (Shares)	1,464,415		688,198
Warrants, Exercisable (Shares)	1,464,415		688,198
Exercise Price Range One [Member] | Warrants [Member]
Warrants, Exercise Price	$ 1		$ 1.2870
Warrants, Outstanding (Shares)	916,217		41,002
Warrants, Exercisable (Shares)	916,217		41,002
Warrants, Expiration Date	Sep. 20, 2022		Apr. 17, 2019
Exercise Price Range Two [Member] | Warrants [Member]
Warrants, Exercise Price	$ 1.2870		$ 1.5620
Warrants, Outstanding (Shares)	41,002		130,284
Warrants, Exercisable (Shares)	41,002		130,284
Warrants, Expiration Date	Apr. 17, 2019		Dec. 31, 2021
Exercise Price Range Three [Member] | Warrants [Member]
Warrants, Exercise Price	$ 1.5620		$ 4.8500
Warrants, Outstanding (Shares)	130,284		5,155
Warrants, Exercisable (Shares)	130,284		5,155
Warrants, Expiration Date	Dec. 31, 2021		Sep. 23, 2019
Exercise Price Range Four [Member] | Warrants [Member]
Warrants, Exercise Price	$ 2.7500		$ 4.8750
Warrants, Outstanding (Shares)	8,000		108,594
Warrants, Exercisable (Shares)	8,000		108,594
Warrants, Expiration Date	Sep. 20, 2022		Sep. 30, 2020
Exercise Price Range Five [Member] | Warrants [Member]
Warrants, Exercise Price	$ 4.8500		$ 5
Warrants, Outstanding (Shares)	5,155		5,000
Warrants, Exercisable (Shares)	5,155		5,000
Warrants, Expiration Date	Sep. 23, 2019		Sep. 22, 2019
Exercise Price Range Six [Member] | Warrants [Member]
Warrants, Exercise Price	$ 4.8750		$ 5.1025
Warrants, Outstanding (Shares)	108,594		10,309
Warrants, Exercisable (Shares)	108,594		10,309
Warrants, Expiration Date	Sep. 30, 2020		Jan. 29, 2019
Exercise Price Range Seven [Member] | Warrants [Member]
Warrants, Exercise Price	$ 5		$ 6.5000
Warrants, Outstanding (Shares)	5,000		8,092
Warrants, Exercisable (Shares)	5,000		8,092
Warrants, Expiration Date	Sep. 22, 2019		Feb. 4, 2019
Exercise Price Range Eight [Member] | Warrants [Member]
Warrants, Exercise Price	$ 5.1025		$ 6.8348
Warrants, Outstanding (Shares)	10,309		145,758
Warrants, Exercisable (Shares)	10,309		145,758
Warrants, Expiration Date	Jan. 29, 2019		Sep. 30, 2020
Exercise Price Range Nine [Member] | Warrants [Member]
Warrants, Exercise Price	$ 6.5000		$ 7.9300
Warrants, Outstanding (Shares)	8,092		86,004
Warrants, Exercisable (Shares)	8,092		86,004
Warrants, Expiration Date	Feb. 4, 2019		Feb. 28, 2021
Exercise Price Range Ten [Member] | Warrants [Member]
Warrants, Exercise Price	$ 6.8348		$ 2.7500
Warrants, Outstanding (Shares)	145,758		148,000
Warrants, Exercisable (Shares)	145,758		148,000
Warrants, Expiration Date	Sep. 30, 2020		Dec. 31, 2021
Exercise Price Range Eleven [Member] | Warrants [Member]
Warrants, Exercise Price	$ 7.9300
Warrants, Outstanding (Shares)	86,004
Warrants, Exercisable (Shares)	86,004
Warrants, Expiration Date	Feb. 28, 2021

Stockholders' Deficiency - Sc_3

Stockholders' Deficiency - Schedule of Stock Options Activity (Details) - $ / shares	Dec. 09, 2017	Jun. 30, 2018	Jun. 30, 2017
Equity [Abstract]
Number of Options, Outstanding, Beginning balance		3,996,167	1,307,749
Number of Options, Exercisable, Beginning balance		3,996,167	1,307,749
Number of Options, Granted		327,150	680,000
Number of Options, Outstanding, Ending balance		4,323,317	1,987,749
Number of Options, Exercisable, Ending balance	1,772,055	4,323,317	1,987,749
Weighted Average Exercise Price, Outstanding, Beginning		$ 3.7634	$ 7.6515
Weighted Average Exercise Price, Exercisable, Beginning		3.7634	7.6515
Weighted Average Exercise Price, Granted		1.1267	3.1037
Weighted Average Exercise Price, Outstanding, Ending	$ 1.45	3.5855	6.0957
Weighted Average Exercise Price, Exercisable, Ending		$ 3.5855	$ 6.0957
Options Outstanding, Weighted Average Remaining Contractual Life (in Years), Beginning		7 years 4 months 17 days
Options Exercisable, Weighted Average Remaining Contractual Life (in Years), Beginning	10 years	7 years 4 months 17 days
Options Outstanding, Weighted Average Remaining Contractual Life (in Years), Granted		4 years 9 months
Options Outstanding, Weighted Average Remaining Contractual Life (in Years), Ending		6 years 5 months 1 day	5 years
Options Exercisable, Weighted Average Remaining Contractual Life (in Years), Ending		6 years 5 months 1 day	5 years

Stockholders' Deficiency - Sc_4

Stockholders' Deficiency - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable (Details) - $ / shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 09, 2017	Dec. 31, 2016
Options Outstanding (Shares)	4,323,317	1,987,749	3,996,167		1,307,749
Options Exercisable (Shares)	4,323,317	1,987,749	3,996,167	1,772,055	1,307,749
Stock Option One [Member]
Options Exercise Price	$ 1.1200	$ 2
Options Outstanding (Shares)	310,388	285,000
Options Exercisable (Shares)	310,388	285,000
Options, Expiration Date	Apr. 5, 2023	Jun. 30, 2022
Stock Option Two [Member]
Options Exercise Price	$ 1.2500	$ 3.9000
Options Outstanding (Shares)	16,762	395,000
Options Exercisable (Shares)	16,762	395,000
Options, Expiration Date	Dec. 7, 2022	Jan. 17, 2022
Stock Option Three [Member]
Options Exercise Price	$ 1.3500	$ 4.5000
Options Outstanding (Shares)	34,000	7,222
Options Exercisable (Shares)	34,000	7,222
Options, Expiration Date	Jul. 28, 2022	Sep. 2, 2021
Stock Option Four [Member]
Options Exercise Price	$ 1.4500	$ 5.6875
Options Outstanding (Shares)	1,849,418	89,686
Options Exercisable (Shares)	1,849,418	89,686
Options, Expiration Date	Dec. 9, 2027	Jun. 30, 2020
Stock Option Five [Member]
Options Exercise Price	$ 1.4500	$ 5.7500
Options Outstanding (Shares)	100,000	2,608
Options Exercisable (Shares)	100,000	2,608
Options, Expiration Date	Dec. 9, 2027	Sep. 12, 2021
Stock Option Six [Member]
Options Exercise Price	$ 2	$ 6.4025
Options Outstanding (Shares)	285,000	27,692
Options Exercisable (Shares)	285,000	27,692
Options, Expiration Date	Jun. 30, 2022	Aug. 18, 2020
Stock Option Seven [Member]
Options Exercise Price	$ 2	$ 6.4025
Options Outstanding (Shares)	25,000	129,231
Options Exercisable (Shares)	25,000	129,231
Options, Expiration Date	Jul. 26, 2022	Aug. 18, 2022
Stock Option Eight [Member]
Options Exercise Price	$ 3.9000	$ 6.4025
Options Outstanding (Shares)	395,000	261,789
Options Exercisable (Shares)	395,000	261,789
Options, Expiration Date	Jan. 17, 2022	Aug. 18, 2025
Stock Option Nine [Member]
Options Exercise Price	$ 4.5000	$ 6.8250
Options Outstanding (Shares)	7,222	8,791
Options Exercisable (Shares)	7,222	8,791
Options, Expiration Date	Sep. 2, 2021	Dec. 11, 2020
Stock Option Ten [Member]
Options Exercise Price	$ 5.6875	$ 7.3775
Options Outstanding (Shares)	89,686	523,077
Options Exercisable (Shares)	89,686	523,077
Options, Expiration Date	Jun. 30, 2020	Mar. 31, 2021
Stock Option Eleven [Member]
Options Exercise Price	$ 5.7500	$ 8.1250
Options Outstanding (Shares)	2,608	169,231
Options Exercisable (Shares)	2,608	169,231
Options, Expiration Date	Sep. 12, 2021	Jun. 30, 2022
Stock Option Twelve[Member]
Options Exercise Price	$ 6.4025	$ 13
Options Outstanding (Shares)	27,692	7,385
Options Exercisable (Shares)	27,692	7,385
Options, Expiration Date	Aug. 18, 2020	Mar. 13, 2019
Stock Option Thirteen [Member]
Options Exercise Price	$ 6.4025	$ 13
Options Outstanding (Shares)	129,231	3,846
Options Exercisable (Shares)	129,231	3,846
Options, Expiration Date	Aug. 18, 2022	Apr. 14, 2019
Stock Option Fourteen [Member]
Options Exercise Price	$ 6.4025	$ 13.9750
Options Outstanding (Shares)	261,789	3,385
Options Exercisable (Shares)	261,789	3,385
Options, Expiration Date	Aug. 18, 2025	Mar. 14, 2024
Stock Option Fifteen [Member]
Options Exercise Price	$ 6.8250	$ 15.4700
Options Outstanding (Shares)	8,791	7,755
Options Exercisable (Shares)	8,791	7,755
Options, Expiration Date	Dec. 11, 2020	Apr. 8, 2020
Stock Option Sixteen [Member]
Options Exercise Price	$ 7.3775	$ 15.9250
Options Outstanding (Shares)	523,077	2,462
Options Exercisable (Shares)	523,077	2,462
Options, Expiration Date	Mar. 31, 2021	Feb. 28, 2024
Stock Option Seventeen [Member]
Options Exercise Price	$ 8.1250	$ 16.0500
Options Outstanding (Shares)	169,231	46,154
Options Exercisable (Shares)	169,231	46,154
Options, Expiration Date	Jun. 30, 2022	Jul. 17, 2019
Stock Option Eighteen [Member]
Options Exercise Price	$ 13	$ 16.6400
Options Outstanding (Shares)	7,385	1,538
Options Exercisable (Shares)	7,385	1,538
Options, Expiration Date	Mar. 13, 2019	Jan. 29, 2020
Stock Option Nineteen [Member]
Options Exercise Price	$ 13	$ 19.5000
Options Outstanding (Shares)	3,846	9,487
Options Exercisable (Shares)	3,846	9,487
Options, Expiration Date	Apr. 14, 2019	Jul. 17, 2022
Stock Option Twenty [Member]
Options Exercise Price	$ 13.9750	$ 19.5000
Options Outstanding (Shares)	3,385	6,410
Options Exercisable (Shares)	3,385	6,410
Options, Expiration Date	Mar. 14, 2024	Aug. 10, 2022
Stock Option Twenty One [Member]
Options Exercise Price	$ 15.4700
Options Outstanding (Shares)	7,755
Options Exercisable (Shares)	7,755
Options, Expiration Date	Apr. 8, 2020
Stock Option Twenty Two [Member]
Options Exercise Price	$ 15.9250
Options Outstanding (Shares)	2,462
Options Exercisable (Shares)	2,462
Options, Expiration Date	Feb. 28, 2024
Stock Option Twenty Three [Member]
Options Exercise Price	$ 16.0500
Options Outstanding (Shares)	46,154
Options Exercisable (Shares)	46,154
Options, Expiration Date	Jul. 17, 2019
Stock Option Twenty Four [Member]
Options Exercise Price	$ 16.6400
Options Outstanding (Shares)	1,538
Options Exercisable (Shares)	1,538
Options, Expiration Date	Jan. 29, 2020
Stock Option Twenty Five [Member]
Options Exercise Price	$ 19.5000
Options Outstanding (Shares)	9,487
Options Exercisable (Shares)	9,487
Options, Expiration Date	Jul. 17, 2022
Stock Option Twenty Six [Member]
Options Exercise Price	$ 19.5000
Options Outstanding (Shares)	6,410
Options Exercisable (Shares)	6,410
Options, Expiration Date	Aug. 10, 2022

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Dec. 09, 2017	Mar. 28, 2017	Jun. 30, 2015	Jun. 30, 2015	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016	Mar. 31, 2013
Accrued compensation	$ 2,557,083
Stock option exercisable term	10 years				7 years 4 months 17 days
Stock option exercise price per share	$ 1.45				$ 3.5855	$ 3.7634	$ 6.0957	$ 7.6515
Options exercisable shares of common stock	1,772,055				4,323,317	3,996,167	1,987,749	1,307,749
Number of common stock shares issued	$ 2,475,561
Employment Agreements [Member] | Tranche One [Member]
Cash bonuses			$ 15,000
Employment Agreements [Member] | Tranche Two [Member]
Cash bonuses			15,000
Employment Agreements [Member] | Tranche Three [Member]
Cash bonuses			30,000
Excess of financing cost			200,000
Aurora Capital LLC [Member]
Reimbursement for legal fees accrued									$ 85,000
Cash placement agent fees		$ 20,000
Common stock purchase warrants, shares							8,000
Common stock warrant for cash					$ 27,648	$ 27,648
Board of Directors [Member]
Cash bonuses				$ 215,000
Executive Officers [Member]
Cash bonuses				195,000
Independent [Member]
Cash bonuses				20,000
Dr. Arnold S.Lippa [Member]
Cash bonuses				75,000
Cash compensation				12,500
Accrued compensation	$ 807,497
Options exercisable shares of common stock	559,595
Jeff E. Margolis [Member]
Cash bonuses				60,000
Cash compensation				10,000
Accrued compensation	$ 560,876
Options exercisable shares of common stock	388,687
Jeff E. Margolis [Member] | Employment Agreements [Member]
Cash bonuses			60,000
Excess of financing cost			100,000
Jeff E. Margolis [Member] | Employment Agreements [Member] | Additional [Member]
Excess of financing cost			250,000
Jeff E. Margolis [Member] | Employment Agreements [Member] | Minimum [Member]
Cash bonuses			$ 15,000
Robert N Weingarten [Member]
Cash bonuses				60,000
Cash compensation				10,000
Accrued compensation	$ 200,350
Options exercisable shares of common stock	138,842
James E. Sapirstein [Member]
Cash bonuses				10,000
Cash compensation				5,000
Accrued compensation	$ 55,000
Options exercisable shares of common stock	38,114
Kathryn MacFarlane [Member]
Cash bonuses				10,000
Cash compensation				$ 5,000
Accrued compensation	$ 55,000
Options exercisable shares of common stock	38,114
Dr. James S. Manuso [Member]
Accrued compensation	$ 878,360
Options exercisable shares of common stock	608,704

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)	Dec. 09, 2017USD ($)$ / sharesshares	Jan. 18, 2017USD ($)	Oct. 26, 2016USD ($)	Jul. 21, 2016USD ($)	Jan. 12, 2016USD ($)	Aug. 18, 2015USD ($)shares	Aug. 18, 2015USD ($)shares	Jun. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Oct. 15, 2014USD ($)	Jun. 27, 2014USD ($)	Mar. 31, 2011USD ($)	Mar. 31, 2010USD ($)	Jun. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2017USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Apr. 05, 2018USD ($)	Dec. 31, 2016$ / sharesshares	Jul. 28, 2016USD ($)	Oct. 30, 2015USD ($)
Unpaid investment banking services				$ 225,000
Arbitrator awarded amount		$ 146,082
Attorneys' fees and costs		$ 47,937
Cash compensation expense	$ 2,557,083
Stock options to purchase | shares														4,323,317	1,987,749	4,323,317	1,987,749	3,996,167		1,307,749
Stock option exercisable term	10 years															7 years 4 months 17 days
Stock option exercise price per share | $ / shares	$ 1.45													$ 3.5855	$ 6.0957	$ 3.5855	$ 6.0957	$ 3.7634		$ 7.6515
Options exercisable shares of common stock | shares	1,772,055													4,323,317	1,987,749	4,323,317	1,987,749	3,996,167		1,307,749
Number of common stock shares issued	$ 2,475,561
Accounts payable																			$ 124,025
Research and development expenses														$ 153,892	$ 574,743	$ 305,227	$ 959,127
Principal cash obligations and commitments														1,380,150		1,380,150
Jeff E. Margolis [Member]
Cash compensation expense	$ 560,876
Cash bonuses									$ 60,000
Options exercisable shares of common stock | shares	388,687
Dr. Arnold S.Lippa [Member]
Cash compensation expense	$ 807,497
Cash bonuses									75,000
Options exercisable shares of common stock | shares	559,595
Dr. James S. Manuso [Member]
Cash compensation expense	$ 878,360
Options exercisable shares of common stock | shares	608,704
James E. Sapirstein [Member]
Cash compensation expense	$ 55,000
Cash bonuses									10,000
Options exercisable shares of common stock | shares	38,114
Kathryn MacFarlane [Member]
Cash compensation expense	$ 55,000
Cash bonuses									10,000
Options exercisable shares of common stock | shares	38,114
Robert N Weingarten [Member]
Cash compensation expense	$ 200,350
Cash bonuses									$ 60,000
Options exercisable shares of common stock | shares	138,842
Employment and Consulting Agreements [Member]
Cash compensation expense
Employment Agreements [Member] | Tranche One [Member]
Cash bonuses								$ 15,000
Employment Agreements [Member] | Tranche Two [Member]
Cash bonuses								15,000
Employment Agreements [Member] | Tranche Three [Member]
Cash bonuses								30,000
Excess of financing cost								200,000
Employment Agreements [Member] | Jeff E. Margolis [Member]
Cash bonuses								60,000
Excess of financing cost								100,000
Employment Agreements [Member] | Jeff E. Margolis [Member] | Additional [Member]
Excess of financing cost								250,000
Employment Agreements [Member] | Minimum [Member] | Jeff E. Margolis [Member]
Cash bonuses								$ 15,000
University of Illinois 2014 Exclusive License Agreement [Member]
License agreement effective date											Sep. 18, 2014
License fee											$ 25,000
Outstanding patent costs											$ 15,840
Charge to operations with stock options														25,000	25,000	50,000	50,000
University of Illinois 2014 Exclusive License Agreement [Member] | Research and Development Expenses [Member]
Minimum annual royalty payment amount																250,000
University of Illinois 2014 Exclusive License Agreement [Member] | Due Within Five Days After Closing Of First Patient Product Phase Two Human Clinical Study [Member]
Payment for sale of product																75,000
University of Illinois 2014 Exclusive License Agreement [Member] | Due Within Five Days After Closing Of First Patient Product Phase Three Human Clinical Trial [Member]
Payment for sale of product																350,000
University of Illinois 2014 Exclusive License Agreement [Member] | Due Within Five Days After First New Drug Application Filing [Member]
Payment for sale of product																500,000
University of Illinois 2014 Exclusive License Agreement [Member] | Due Within Twelve Months After First Commercial Sale Of Product Member [Member]
Payment for sale of product																1,000,000
University of Illinois 2014 Exclusive License Agreement [Member] | Minimum [Member]
Minimum annual royalty payment amount																$ 100,000		$ 100,000
Percentage of royalty on net sale																4.00%
Percentage of payment on sub licensee revenue																12.50%
University of Illinois 2014 Exclusive License Agreement [Member] | Maximum [Member] | First Sale Of Product [Member]
Minimum annual royalty payment amount																$ 150,000
University of Illinois 2014 Exclusive License Agreement [Member] | Maximum [Member] | First Commercial Sale Of Product [Member]
Minimum annual royalty payment amount																200,000
Neuroscience and Mental Health Institute at University of Alberta [Member]
Research grants award amount					$ 111,000
Additional cost budgeted under research grant					65,000
Funding cash installments					16,000
Payments to patent costs					15,000
Underwrite additional budgeted costs					$ 15,000
Accounts payable																		16,207
Foreign conversion exchange rate					0.76
Research and development expenses																0	0
Neuroscience and Mental Health Institute at University of Alberta [Member] | CAD [Member]
Research grants award amount					$ 146,000
Additional cost budgeted under research grant					85,000
Funding cash installments					21,000
Payments to patent costs					20,000
Underwrite additional budgeted costs					$ 20,000
Accounts payable																		$ 21,222
Foreign conversion exchange rate					1
Duke University Clinical Trial Agreement [Member]
Amount payable																					$ 678,327	$ 678,327
Budgeted cost			$ 35,958
Richard Purcell [Member] | DNA Healthlink, Inc [Member]
Cash compensation expense																	75,000
Richard Purcell [Member] | DNA Healthlink, Inc [Member]
Cash fee										$ 12,500
Cash compensation expense														37,500	37,500	75,000
Mr. Manuso [Member]
Cash compensation expense						$ 375,000
Percentage of annual bonus from base salary						50.00%
Stock options to purchase | shares						261,789	261,789
Health plan for employees expense						$ 1,200
Maximum health coverage amount per month						$ 1,000
Dr. Manuso [Member]
Cash compensation expense	$ 878,360													$ 103,650	103,650	$ 207,300	207,300
Stock options to purchase | shares														608,704		608,704
Dr. Arnold S.Lippa [Member]
Cash compensation expense							$ 300,000							$ 84,900	$ 84,900	$ 169,800	$ 169,800
Percentage of annual bonus from base salary							50.00%
Stock options to purchase | shares						30,769	30,769
Health plan for employees expense							$ 1,200
Maximum health coverage amount per month							1,000
President And Chief Executive Officer [Member]
Cash compensation expense																$ 94,758
Dr. Lippa [Member]
Cash compensation expense	$ 807,497
Stock options to purchase | shares														559,595		559,595
Mr Margolis [Member]
Cash compensation expense							$ 195,000
Stock options to purchase | shares						30,769	30,769
Health plan for employees expense							$ 1,200
Maximum health coverage amount per month							1,000
Mr Margolis [Member] | Minimum [Member]
Bonuses						$ 65,000	65,000
Mr Margolis [Member] | Maximum [Member]
Bonuses						$ 125,000	$ 125,000
Dr. Manuso, Dr. Lippa, Mr. Margolis and Mr. Weingarten [Member]
Net proceeds from offering cost																$ 2,000,000
Biovail [Member]
Reimbursement related expenses													$ 15,000,000
Payments for future potential												$ 15,150,000
Additional payments received upto												$ 15,000,000

Commitments and Contingencies -

Commitments and Contingencies - Summary of Principal Cash Obligations and Commitments (Details)	Jun. 30, 2018USD ($)
2,018	$ 484,250
2,019	595,900
2,020	100,000
2,021	100,000
2,022	100,000
Total	1,380,150
Research and Development Contracts [Member]
2,018
2,019
2,020
2,021
2,022
Total
Clinical Trial Agreements [Member]
2,018
2,019
2,020
2,021
2,022
Total
License Agreements [Member]
2,018	50,000
2,019	100,000
2,020	100,000
2,021	100,000
2,022	100,000
Total	450,000
Employment and Consulting Agreements [Member]
2,018	434,250	[1]
2,019	495,900	[1]
2,020		[1]
2,021		[1]
2,022		[1]
Total	$ 930,150	[1]
[1]	The payment of such amounts has been deferred indefinitely, as described above at "“Employment Agreements". Does not include amounts after September 30, 2018 for Dr. Manuso as his resignation was effective on such date. 2018 obligations include six months of employment agreement obligations for Dr. Lippa and Mr. Margolis as their employment contracts renewed on September 30, 2018 (See Note 9. Subsequent Events) and 2019 obligations include nine months of obligations through September 30, 2019.

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Sep. 12, 2018	Dec. 09, 2017	Jun. 30, 2018	Jun. 30, 2017
Offering of common stock		$ 2,475,561
Proceeds from issuance of common stock				$ 350,000
Debt conversion, shares issued			15,669
Debt instrument interest rate			8.93%
Subsequent Event [Member] | 2018 Unit Offering [Member]
Offering of common stock	$ 1,500,000
Initial closing amount	250,750
Proceeds from issuance of common stock	$ 200,750
Debt conversion, shares issued	50,000
Sales price per share	$ 1.05
Warrants exercisable date	Apr. 30, 2023
Purchase price, percentage	150.00%
Percentage of investor beneficially outstanding shares of common stock	4.99%
Redemption of warrants price per share	$ 0.001
Common stock purchase of warrants	238,814
Warrant description	The warrants are also subject to redemption by the Company at $0.001 per share upon ten (10) days written notice if the Company’s common stock closes at $3.00 or more for any five (5) consecutive trading days. In total, 238,814 shares of the Company’s common stock and 238,814 common stock purchase warrants were purchased.
Debt instrument principal amount	$ 100,000
Debt instrument interest rate	10.00%
Gross proceeds	$ 15,000,000
Subsequent Event [Member] | 2018 Unit Offering [Member] | Dr. Arnold S.Lippa [Member]
Debt instrument principal amount	50,000
Subsequent Event [Member] | 2018 Unit Offering [Member] | Dr. James S. Manuso [Member]
Debt instrument principal amount	$ 50,000